Author: "Cavaletti, G." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Cavaletti, G."' showing total 2,156 results

Start Over Author "Cavaletti, G."

2,156 results on '"Cavaletti, G."'

1. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

Author: Bergamaschi, Roberto, Beghi, Ettore, Bosetti, Cristina, Ponzio, Michela, Santucci, Claudia, Lepore, Vito, Mosconi, Paola, Aguglia, U., Amato, M. P., Ancona, A. L., Ardito, B., Avolio, C., Balgera, R., Banfi, P., Barcella, V., Barone, P., Bellantonio, P., Berardinelli, A., Bergamaschi, R., Bertora, P., Bianchi, M., Bramanti, P., Morra, V. Brescia, Brichetto, G., Brioschi, A. M., Buccafusca, M., Bucello, S., Busillo, V., Calchetti, B., Cantello, R., Capobianco, M., Capone, F., Capone, L., Cargnelutti, D., Carrozzi, M., Cartechini, E., Cavaletti, G., Cavalla, P., Celani, M. G., Clerici, R., Clerico, M., Cocco, E., Confalonieri, P., Coniglio, M. G., Conte, A., Corea, F., Cottone, S., Crociani, P., D’Andrea, F., Danni, M. C., De Luca, G., de Pascalis, D., De Riz, M., De Robertis, F., De Rosa, G., De Stefano, N., Corte, M. Della, Di Sapio, A., Docimo, R., Falcini, M., Falcone, N., Fermi, S., Ferraro, E., Ferrò, M. T., Fortunato, M., Foschi, M., Gajofatto, A., Gallo, A., Gallo, P., Gatto, M., Gazzola, P., Giordano, A., Granella, F., Grasso, M. F., Grasso, M. G., Grimaldi, L. M. E., Iaffaldano, P., Imperiale, D., Inglese, M., Iodice, R., Leva, S., Luezzi, V., Lugaresi, A., Lus, G., Maimone, D., Mancinelli, L., Maniscalco, G. T., Marfia, G. A., Marini, B., Marson, A., Mascoli, N., Massacesi, L., Melani, F., Merello, M., Meucci, G., Mirabella, M., Montepietra, S., Nasuelli, D., Nicolao, P., Passantino, F., Patti, F., Peresson, M., Pesci, I., Piantadosi, C., Piras, M. L., Pizzorno, M., Plewnia, K., Pozzilli, C., Protti, A., Quatrale, R., Realmuto, S., Ribizzi, G., Rinalduzzi, S., Rini, A., Romano, S., Romeo, M., Ronzoni, M., Rossi, P., Rovaris, M., Salemi, G., Santangelo, G., Santangelo, M., Santuccio, G., Sarchielli, P., Sinisi, L., Sola, P., Solaro, C., Spitaleri, D., Strumia, S., Tassinari, T., Tonietti, S., Tortorella, C., Totaro, R., Tozzo, A., Trivelli, G., Ulivelli, M., Valentino, P., Venturi, S., Vianello, M., Zaffaroni, M., Zarbo, R., Trojano, Maria, Battaglia, Mario Alberto, Capobianco, Marco, Pugliatti, Maura, Ulivelli, Monica, Mosconi, Paola, Gasperini, Claudio, Patti, Francesco, Amato, Maria Pia, Bergamaschi, Roberto, and Comi, Giancarlo
Published: 2022
Full Text: View/download PDF

2. Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants

Author: De&nbsp, Lorenzo, A, Liberatore, G, Doneddu, P, Manganelli, F, Cocito, D, Briani, C, Fazio, R, Mazzeo, A, Schenone, A, Di&nbsp, Stefano, V, Cosentino, G, Marfia, G, Benedetti, L, Carpo, M, Filosto, M, Antonini, G, Clerici, A, Luigetti, M, Matà, S, Rosso, T, Lucchetta, M, Siciliano, G, Lauria&nbsp, Pinter, G, Cavaletti, G, Inghilleri, M, Cantisani, T, Notturno, F, Ricciardi, D, Habetswallner, F, Spina, E, Peci, E, Salvalaggio, A, Falzone, Y, Strano, C, Gentile, L, Vegezzi, E, Mataluni, G, Cotti&nbsp, Piccinelli, S, Leonardi, L, Romano, A, Nobile-Orazio, E, Lorenzo A., Liberatore G., Doneddu P. E., Manganelli F., Cocito D., Briani C., Fazio R., Mazzeo A., Schenone A., Stefano V., Cosentino G., Marfia G. A., Benedetti L., Carpo M., Filosto M., Antonini G., Clerici A. M., Luigetti M., Matà S., Rosso T., Lucchetta M., Siciliano G., Pinter G., Cavaletti G., Inghilleri M., Cantisani T., Notturno F., Ricciardi D., Habetswallner F., Spina E., Peci E., Salvalaggio A., Falzone Y., Strano C., Gentile L., Vegezzi E., Mataluni G., Piccinelli S., Leonardi L., Romano A., Nobile-Orazio E., De&nbsp, Lorenzo, A, Liberatore, G, Doneddu, P, Manganelli, F, Cocito, D, Briani, C, Fazio, R, Mazzeo, A, Schenone, A, Di&nbsp, Stefano, V, Cosentino, G, Marfia, G, Benedetti, L, Carpo, M, Filosto, M, Antonini, G, Clerici, A, Luigetti, M, Matà, S, Rosso, T, Lucchetta, M, Siciliano, G, Lauria&nbsp, Pinter, G, Cavaletti, G, Inghilleri, M, Cantisani, T, Notturno, F, Ricciardi, D, Habetswallner, F, Spina, E, Peci, E, Salvalaggio, A, Falzone, Y, Strano, C, Gentile, L, Vegezzi, E, Mataluni, G, Cotti&nbsp, Piccinelli, S, Leonardi, L, Romano, A, Nobile-Orazio, E, Lorenzo A., Liberatore G., Doneddu P. E., Manganelli F., Cocito D., Briani C., Fazio R., Mazzeo A., Schenone A., Stefano V., Cosentino G., Marfia G. A., Benedetti L., Carpo M., Filosto M., Antonini G., Clerici A. M., Luigetti M., Matà S., Rosso T., Lucchetta M., Siciliano G., Pinter G., Cavaletti G., Inghilleri M., Cantisani T., Notturno F., Ricciardi D., Habetswallner F., Spina E., Peci E., Salvalaggio A., Falzone Y., Strano C., Gentile L., Vegezzi E., Mataluni G., Piccinelli S., Leonardi L., Romano A., and Nobile-Orazio E.
Abstract: Background and purpose: There are different criteria for the diagnosis of different variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) guidelines provide specific clinical criteria for each CIDP variant even if their therapeutical impact has not been investigated. Methods: We applied the clinical criteria for CIDP variants of the 2021 EAN/PNS guidelines to 369 patients included in the Italian CIDP database who fulfilled the 2021 EAN/PNS electrodiagnostic criteria for CIDP. Results: According to the 2021 EAN/PNS clinical criteria, 245 patients achieved a clinical diagnosis of typical CIDP or CIDP variant (66%). We identified 106 patients with typical CIDP (29%), 62 distal CIDP (17%), 28 multifocal or focal CIDP (7%), four sensory CIDP (1%), 27 sensory-predominant CIDP (7%), 10 motor CIDP (3%), and eight motor-predominant CIDP (2%). Patients with multifocal, distal, and sensory CIDP had milder impairment and symptoms. Patients with multifocal CIDP had less frequently reduced conduction velocity and prolonged F-wave latency and had lower levels of cerebrospinal fluid protein. Patients with distal CIDP more frequently had reduced distal compound muscle action potentials. Patients with motor CIDP did not improve after steroid therapy, whereas those with motor-predominant CIDP did. None of the patients with sensory CIDP responded to steroids, whereas most of those with sensory-predominant CIDP did. Conclusions: The 2021 EAN/PNS criteria for CIDP allow a better characterization of CIDP variants, permitting their distinction from typical CIDP and more appropriate treatment for patients.
Published: 2024

3. A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata

Author: Anderson, S, Cavaletti, G, Hood, L, Polydefkis, M, Herrmann, D, Rance, G, King, B, Mcmichael, A, Senna, M, Kim, B, Napatalung, L, Wolk, R, Zwillich, S, Schaefer, G, Gong, Y, Sisson, M, Posner, H, Anderson S., Cavaletti G., Hood L. J., Polydefkis M., Herrmann D. N., Rance G., King B., McMichael A. J., Senna M. M., Kim B. S., Napatalung L., Wolk R., Zwillich S. H., Schaefer G., Gong Y., Sisson M., Posner H. B., Anderson, S, Cavaletti, G, Hood, L, Polydefkis, M, Herrmann, D, Rance, G, King, B, Mcmichael, A, Senna, M, Kim, B, Napatalung, L, Wolk, R, Zwillich, S, Schaefer, G, Gong, Y, Sisson, M, Posner, H, Anderson S., Cavaletti G., Hood L. J., Polydefkis M., Herrmann D. N., Rance G., King B., McMichael A. J., Senna M. M., Kim B. S., Napatalung L., Wolk R., Zwillich S. H., Schaefer G., Gong Y., Sisson M., and Posner H. B.
Abstract: Reversible axonal swelling and brainstem auditory evoked potential (BAEP) changes were observed in standard chronic (9-month) toxicology studies in dogs treated with ritlecitinib, an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor, at exposures higher than the approved 50-mg human dose. To evaluate the clinical relevance of the dog toxicity finding, this phase 2a, double-blind study assessed BAEP changes and intraepidermal nerve fiber (IENF) histology in adults with alopecia areata treated with ritlecitinib. Patients were randomized to receive oral ritlecitinib 50 mg once daily (QD) with a 4-week loading dose of 200 mg QD or placebo for 9 months (placebo-controlled phase); they then entered the active-therapy extension and received ritlecitinib 50 mg QD (with a 4-week loading dose of 200 mg in patients switching from placebo). Among the 71 patients, no notable mean differences in change from baseline (CFB) in Waves I–V interwave latency (primary outcome) or Wave V amplitude on BAEP at a stimulus intensity of 80 dB nHL were observed in the ritlecitinib or placebo group at Month 9, with no notable differences in interwave latency or Wave V amplitude between groups. The CFB in mean or median IENF density and in percentage of IENFs with axonal swellings was minimal and similar between groups at Month 9. Ritlecitinib treatment was also not associated with an imbalanced incidence of neurological and audiological adverse events. These results provide evidence that the BAEP and axonal swelling finding in dogs are not clinically relevant in humans.
Published: 2024

4. Electrodiagnostic subtyping in Guillain–Barré syndrome patients in the International Guillain–Barré Outcome Study

Author: Arends, S, Drenthen, J, de Koning, L, van den Bergh, P, Hadden, R, Kuwabara, S, Reisin, R, Shahrizaila, N, Ajroud-Driss, S, Antonini, G, Attarian, S, Balducci, C, Bertorini, T, Brannagan, T, Cavaletti, G, Chao, C, Chavada, G, Dillmann, K, Dimachkie, M, Galassi, G, Gutierrez-Gutierrez, G, Harbo, T, Islam, B, Islam, Z, Katzberg, H, Kusunoki, S, Manganelli, F, Miller, J, Pardo, J, Pereon, Y, Rajabally, Y, Sindrup, S, Stettner, M, Uncini, A, Verhamme, C, Vytopil, M, Waheed, W, Jacobs, B, Cornblath, D, Addington, J, Badrising, U, Barroso, F, Bateman, K, Bella, I, Benedetti, L, van den Berg, B, Bhavaraju-Sanka, R, Briani, C, Buermann, J, Busby, M, Butterworth, S, Casasnovas, C, Chen, S, Claeys, K, Conti, E, Cosgrove, J, Dalakas, M, van Damme, P, Dardiotis, E, Davidson, A, Doets, A, van Doorn, P, Echaniz-Laguna, A, Eftimov, F, Faber, K, Fazio, R, Feasby, T, Fehmi, J, Fokke, C, Fujioka, T, Fulgenzi, E, Garssen, M, Gijsbers, C, Gilchrist, J, Gilhuis, J, Goldstein, J, Gorson, K, Goyal, N, Granit, V, Gutmann, L, Hartung, H, Holt, J, Hsieh, S, Htut, M, Hughes, R, Jerico-Pascual, I, Kaida, K, Karafiath, S, Khoshnoodi, M, Kiers, L, Kleiweg, R, Kokubun, N, Kolb, N, van Koningsveld, R, van der Kooi, A, Kramers, H, Kuitwaard, K, Kwan, J, Ladha, S, Lassen, L, Lawson, V, Lehmann, H, Cejas, L, Leonhard, S, Luijten, L, Lunn, M, Manji, H, Marfia, G, Infante, C, Martin-Aguilar, L, Martinez-Hernandez, E, Mataluni, G, Mattiazzi, M, Mcdermott, C, Meekins, G, Mohammad, Q, Monges, S, de la Tassa, G, Nascimbene, C, Nobile-Orazio, E, Nowak, R, Osei-Bonsu, M, Pelouto, F, Pulley, M, Gutierrez, L, Reddel, S, van der Ree, T, Rinaldi, S, Ripellino, P, Roberts, R, Rojas-Marcos, I, Roodbol, J, Rudnicki, S, Sachs, G, Samijn, J, Santoro, L, Schenone, A, Tous, M, Sheikh, K, Silvestri, N, Sundrup, S, Sommer, C, Stein, B, Stino, A, Thomma, R, Twydell, P, Varrato, J, Vermeij, F, Verschuuren, J, Visser, L, Walgaard, C, Wang, Y, Willison, H, Wirtz, P, van Woerkom, M, Zivkovic, S, Arends S., Drenthen J., de Koning L., van den Bergh P., Hadden R. D. M., Kuwabara S., Reisin R. C., Shahrizaila N., Ajroud-Driss S., Antonini G., Attarian S., Balducci C., Bertorini T., Brannagan T. H., Cavaletti G., Chao C. -C., Chavada G., Dillmann K. -U., Dimachkie M. M., Galassi G., Gutierrez-Gutierrez G., Harbo T., Islam B., Islam Z., Katzberg H., Kusunoki S., Manganelli F., Miller J. A. L., Pardo J., Pereon Y., Rajabally Y. A., Sindrup S., Stettner M., Uncini A., Verhamme C., Vytopil M., Waheed W., Jacobs B. C., Cornblath D. R., Addington J. M., Badrising U. A., Barroso F. A., Bateman K., Bella I., Benedetti L., van den Berg B., Bhavaraju-Sanka R., Briani C., Buermann J., Busby M., Butterworth S., Casasnovas C., Chen S., Claeys K., Conti E., Cosgrove J. S., Dalakas M., van Damme P., Dardiotis E., Davidson A., Doets A., van Doorn P., Echaniz-Laguna A., Eftimov F., Faber K. G., Fazio R., Feasby T. E., Fehmi J., Fokke C., Fujioka T., Fulgenzi E., Garssen M. P. J., Gijsbers C. J., Gilchrist J. M., Gilhuis J., Goldstein J. M., Gorson K. C., Goyal N., Granit V., Gutmann L., Hartung H. -P., Holt J. K. L., Hsieh S. -T., Htut M., Hughes R. A. C., Jerico-Pascual I., Kaida K., Karafiath S., Khoshnoodi M. A., Kiers L., Kleiweg R. P., Kokubun N., Kolb N. A., van Koningsveld R., van der Kooi A. J., Kramers H., Kuitwaard K., Kwan J. Y., Ladha S. S., Lassen L. L., Lawson V. H., Lehmann H., Cejas L. L., Leonhard S. E., Luijten L., Lunn M. P. T., Manji H., Marfia G. A., Infante C. M., Martin-Aguilar L., Martinez-Hernandez E., Mataluni G., Mattiazzi M., McDermott C., Meekins G., Mohammad Q. D., Monges S., de la Tassa G. M., Nascimbene C., Nobile-Orazio E., Nowak R. J., Osei-Bonsu M., Pelouto F., Pulley M. T., Gutierrez L. Q., Reddel S. W., van der Ree T., Rinaldi S., Ripellino P., Roberts R. C., Rojas-Marcos I., Roodbol J., Rudnicki S. A., Sachs G. M., Samijn J. P. A., Santoro L., Schenone A., Tous M. J. S., Sheikh K. A., Silvestri N. J., Sundrup S. H., Sommer C., Stein B., Stino A. M., Thomma R. C. M., Twydell P., Varrato J. D., Vermeij F. H., Verschuuren J., Visser L. H., Walgaard C., Wang Y., Willison H. J., Wirtz P. W., van Woerkom M., Zivkovic S. A., Arends, S, Drenthen, J, de Koning, L, van den Bergh, P, Hadden, R, Kuwabara, S, Reisin, R, Shahrizaila, N, Ajroud-Driss, S, Antonini, G, Attarian, S, Balducci, C, Bertorini, T, Brannagan, T, Cavaletti, G, Chao, C, Chavada, G, Dillmann, K, Dimachkie, M, Galassi, G, Gutierrez-Gutierrez, G, Harbo, T, Islam, B, Islam, Z, Katzberg, H, Kusunoki, S, Manganelli, F, Miller, J, Pardo, J, Pereon, Y, Rajabally, Y, Sindrup, S, Stettner, M, Uncini, A, Verhamme, C, Vytopil, M, Waheed, W, Jacobs, B, Cornblath, D, Addington, J, Badrising, U, Barroso, F, Bateman, K, Bella, I, Benedetti, L, van den Berg, B, Bhavaraju-Sanka, R, Briani, C, Buermann, J, Busby, M, Butterworth, S, Casasnovas, C, Chen, S, Claeys, K, Conti, E, Cosgrove, J, Dalakas, M, van Damme, P, Dardiotis, E, Davidson, A, Doets, A, van Doorn, P, Echaniz-Laguna, A, Eftimov, F, Faber, K, Fazio, R, Feasby, T, Fehmi, J, Fokke, C, Fujioka, T, Fulgenzi, E, Garssen, M, Gijsbers, C, Gilchrist, J, Gilhuis, J, Goldstein, J, Gorson, K, Goyal, N, Granit, V, Gutmann, L, Hartung, H, Holt, J, Hsieh, S, Htut, M, Hughes, R, Jerico-Pascual, I, Kaida, K, Karafiath, S, Khoshnoodi, M, Kiers, L, Kleiweg, R, Kokubun, N, Kolb, N, van Koningsveld, R, van der Kooi, A, Kramers, H, Kuitwaard, K, Kwan, J, Ladha, S, Lassen, L, Lawson, V, Lehmann, H, Cejas, L, Leonhard, S, Luijten, L, Lunn, M, Manji, H, Marfia, G, Infante, C, Martin-Aguilar, L, Martinez-Hernandez, E, Mataluni, G, Mattiazzi, M, Mcdermott, C, Meekins, G, Mohammad, Q, Monges, S, de la Tassa, G, Nascimbene, C, Nobile-Orazio, E, Nowak, R, Osei-Bonsu, M, Pelouto, F, Pulley, M, Gutierrez, L, Reddel, S, van der Ree, T, Rinaldi, S, Ripellino, P, Roberts, R, Rojas-Marcos, I, Roodbol, J, Rudnicki, S, Sachs, G, Samijn, J, Santoro, L, Schenone, A, Tous, M, Sheikh, K, Silvestri, N, Sundrup, S, Sommer, C, Stein, B, Stino, A, Thomma, R, Twydell, P, Varrato, J, Vermeij, F, Verschuuren, J, Visser, L, Walgaard, C, Wang, Y, Willison, H, Wirtz, P, van Woerkom, M, Zivkovic, S, Arends S., Drenthen J., de Koning L., van den Bergh P., Hadden R. D. M., Kuwabara S., Reisin R. C., Shahrizaila N., Ajroud-Driss S., Antonini G., Attarian S., Balducci C., Bertorini T., Brannagan T. H., Cavaletti G., Chao C. -C., Chavada G., Dillmann K. -U., Dimachkie M. M., Galassi G., Gutierrez-Gutierrez G., Harbo T., Islam B., Islam Z., Katzberg H., Kusunoki S., Manganelli F., Miller J. A. L., Pardo J., Pereon Y., Rajabally Y. A., Sindrup S., Stettner M., Uncini A., Verhamme C., Vytopil M., Waheed W., Jacobs B. C., Cornblath D. R., Addington J. M., Badrising U. A., Barroso F. A., Bateman K., Bella I., Benedetti L., van den Berg B., Bhavaraju-Sanka R., Briani C., Buermann J., Busby M., Butterworth S., Casasnovas C., Chen S., Claeys K., Conti E., Cosgrove J. S., Dalakas M., van Damme P., Dardiotis E., Davidson A., Doets A., van Doorn P., Echaniz-Laguna A., Eftimov F., Faber K. G., Fazio R., Feasby T. E., Fehmi J., Fokke C., Fujioka T., Fulgenzi E., Garssen M. P. J., Gijsbers C. J., Gilchrist J. M., Gilhuis J., Goldstein J. M., Gorson K. C., Goyal N., Granit V., Gutmann L., Hartung H. -P., Holt J. K. L., Hsieh S. -T., Htut M., Hughes R. A. C., Jerico-Pascual I., Kaida K., Karafiath S., Khoshnoodi M. A., Kiers L., Kleiweg R. P., Kokubun N., Kolb N. A., van Koningsveld R., van der Kooi A. J., Kramers H., Kuitwaard K., Kwan J. Y., Ladha S. S., Lassen L. L., Lawson V. H., Lehmann H., Cejas L. L., Leonhard S. E., Luijten L., Lunn M. P. T., Manji H., Marfia G. A., Infante C. M., Martin-Aguilar L., Martinez-Hernandez E., Mataluni G., Mattiazzi M., McDermott C., Meekins G., Mohammad Q. D., Monges S., de la Tassa G. M., Nascimbene C., Nobile-Orazio E., Nowak R. J., Osei-Bonsu M., Pelouto F., Pulley M. T., Gutierrez L. Q., Reddel S. W., van der Ree T., Rinaldi S., Ripellino P., Roberts R. C., Rojas-Marcos I., Roodbol J., Rudnicki S. A., Sachs G. M., Samijn J. P. A., Santoro L., Schenone A., Tous M. J. S., Sheikh K. A., Silvestri N. J., Sundrup S. H., Sommer C., Stein B., Stino A. M., Thomma R. C. M., Twydell P., Varrato J. D., Vermeij F. H., Verschuuren J., Visser L. H., Walgaard C., Wang Y., Willison H. J., Wirtz P. W., van Woerkom M., and Zivkovic S. A.
Abstract: Background and purpose: Various electrodiagnostic criteria have been developed in Guillain–Barré syndrome (GBS). Their performance in a broad representation of GBS patients has not been evaluated. Motor conduction data from the International GBS Outcome Study (IGOS) cohort were used to compare two widely used criterion sets and relate these to diagnostic amyotrophic lateral sclerosis criteria. Methods: From the first 1500 patients in IGOS, nerve conduction studies from 1137 (75.8%) were available for the current study. These patients were classified according to nerve conduction studies criteria proposed by Hadden and Rajabally. Results: Of the 1137 studies, 68.3% (N = 777) were classified identically according to criteria by Hadden and Rajabally: 111 (9.8%) axonal, 366 (32.2%) demyelinating, 195 (17.2%) equivocal, 35 (3.1%) inexcitable and 70 (6.2%) normal. Thus, 360 studies (31.7%) were classified differently. The areas of differences were as follows: 155 studies (13.6%) classified as demyelinating by Hadden and axonal by Rajabally; 122 studies (10.7%) classified as demyelinating by Hadden and equivocal by Rajabally; and 75 studies (6.6%) classified as equivocal by Hadden and axonal by Rajabally. Due to more strictly defined cutoffs fewer patients fulfilled demyelinating criteria by Rajabally than by Hadden, making more patients eligible for axonal or equivocal classification by Rajabally. In 234 (68.6%) axonal studies by Rajabally the revised El Escorial (amyotrophic lateral sclerosis) criteria were fulfilled; in axonal cases by Hadden this was 1.8%. Conclusions and discussion: This study shows that electrodiagnosis in GBS is dependent on the criterion set utilized, both of which are based on expert opinion. Reappraisal of electrodiagnostic subtyping in GBS is warranted.
Published: 2024

5. Mobile Applications to Support Multiple Sclerosis Communities: The Post-COVID-19 Scenario

Author: Vacchi, L, Zirone, E, Strina, V, Cavaletti, G, Ferrarese, C, Vacchi L., Zirone E., Strina V., Cavaletti G., Ferrarese C., Vacchi, L, Zirone, E, Strina, V, Cavaletti, G, Ferrarese, C, Vacchi L., Zirone E., Strina V., Cavaletti G., and Ferrarese C.
Abstract: Introduction: The increase in the use of mobile apps since the COVID-19 pandemic, even among people with multiple sclerosis (PwMS) and health care providers (HCPs), has enabled access to reliable information, symptoms monitoring and management, and social connections. The pandemic has undoubtedly contributed to the acceleration of the "digital revolution." But how far has it progressed for the MS communities?Methods: Italian Google Play and App Store were queried, selecting MS-specific apps in English or Italian language and usable by a wide public.Results: Fifty-four (n = 54) MS-specific apps were identified; most were PwMS-oriented (83%), free of charge (94%), and in English language (76%). The 45 PwMS-oriented apps focused on increasing MS knowledge (71%), tracking symptoms (33%), and promoting networking with peers or HCPs (38%). The 13 HCPs-oriented tools addressed education and updates on MS (62%), disease assessment and management (54%), and research (15%). Google Search tool was also queried to find non-MS-specific apps to fulfill some unmet domains (as sleep, pain, sexual or mental health). Twenty-four additional apps were listed to provide a valuable contribution.Conclusion: The "digital revolution" led to increasingly customized tools for PwMS, especially as m-health or social-networking apps. However, apps to support other specific MS-relevant domains, appealing HCPs-oriented apps, and specific mobile tools for MS caregivers are still lacking. The absence of data assessing the usability and quality of MS apps in ecologically contexts leads to not reliable conclusions about potential benefits. A strong dialogue between MS communities and the digital industry is encouraged to fill this gap.
Published: 2024

6. CENTRAL AND PERIPHERAL MICROVASCULAR NETWORK IS ABNORMAL IN RATS WITH PAINFUL-CHEMOTHERAPY INDUCED NEUROPATHY: NEW PATHOPHYSIOLOGICAL MECHANISMS OVER THE HORIZON?

Author: Carozzi, V, Rodriguez-Menendez, V, Pozzi, E, Canta, A, Chiorazzi, A, Cordani, N, Alberti, P, Meregalli, C, Longo, E, Saccomano, G, Tromba, G, Donà, E, Cavaletti, G, Zippo, A, Carozzi VA, Rodriguez-Menendez V, Pozzi E, Canta A, Chiorazzi A, Cordani N, Alberti P, Meregalli C, Longo E, Saccomano G, Tromba G, Donà E, Cavaletti G, Zippo AG, Carozzi, V, Rodriguez-Menendez, V, Pozzi, E, Canta, A, Chiorazzi, A, Cordani, N, Alberti, P, Meregalli, C, Longo, E, Saccomano, G, Tromba, G, Donà, E, Cavaletti, G, Zippo, A, Carozzi VA, Rodriguez-Menendez V, Pozzi E, Canta A, Chiorazzi A, Cordani N, Alberti P, Meregalli C, Longo E, Saccomano G, Tromba G, Donà E, Cavaletti G, and Zippo AG
Published: 2024

7. Alterations of gut microbiota composition in post-finasteride patients: a pilot study

Author: Borgo, F., Macandog, A. D., Diviccaro, S., Falvo, E., Giatti, S., Cavaletti, G., and Melcangi, R. C.
Published: 2021
Full Text: View/download PDF

8. Repurposing chemotherapy‐induced peripheral neuropathy grading.

Author: Velasco, Roser, Argyriou, Andreas A., Cornblath, David R., Bruna, Pere, Alberti, Paola, Rossi, Emanuela, Merkies, Ingemar S. J., Psimaras, Dimitri, Briani, Chiara, Lalisang, Roy I., Schenone, Angelo, Cavaletti, Guido, Bruna, Jordi, Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, M. L., Alberti, P., and Binda, D.
Subjects: PATIENTS' attitudes, HIERARCHICAL clustering (Cluster analysis), PERIPHERAL neuropathy, DISCRIMINANT analysis, PHYSICIANS
Abstract: Background and Purpose: Chemotherapy‐induced peripheral neuropathy (CIPN) is perceived differently by patients and physicians, complicating its assessment. Current recommendations advocate combining clinical and patient‐reported outcomes measures, but this approach can be challenging in patient care. This multicenter European study aims to bridge the gap between patients' perceptions and neurological impairments by aligning both perspectives to improve treatment decision‐making. Methods: Data were pooled from two prospective studies of subjects (n = 372) with established CIPN. Patient and physician views regarding CIPN were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI‐CTCAE), Total Neuropathy Scale–clinical version (TNSc) items, and the disease‐specific quality of life ‐ Chemotherapy‐Induced Peripheral Neuropathy questionnaire (QLQ‐CIPN20) from the European Organization for Research and Treatment of Cancer (EORTC). To identify inherent neurotoxic severity patterns, we employed hierarchical cluster analysis optimized with k‐means clustering and internally validated by discriminant functional analysis. Results: Both NCI‐CTCAE and TNSc demonstrated a significant difference in the distribution of severity grades in relation to QLQ‐CIPN20 scores. However, a proportion of subjects with different neurotoxic severity grades exhibited overlapping QLQ‐CIPN20 scores. We identified three distinct clusters classifying subjects as having severely impaired, intermediately impaired, and mildly impaired CIPN based on TNSc and QLQ‐CIPN20 scores. No differences in demographics, cancer type distribution, or class of drug received were observed. Conclusions: Our results confirm the heterogeneity in CIPN perception between patients and physicians and identify three well‐differentiated subgroups of patients delineated by degree of CIPN impairment based on scores derived from TNSc and QLQ‐CIPN20. A more refined assessment of CIPN could potentially be achieved using the calculator tool derived from the cluster equations in this study. This tool, which facilitates individual patient classification, requires prospective validation. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

9. Angiogenesis-Related New Mechanisms for Chemotherapy-Induced Painful Peripheral Neuropathy in the Rat

Author: Carozzi, V, Rodriguez-Menendez, V, Pozzi, E, Canta, A, Chiorazzi, A, Ballarini, E, Alberti, P, Meregalli, C, Cordani, N, Donà, E, Ramazzotti, D, Bravin, A, Tromba, G, Cavaletti, G, Giuliano Zippo, A, Valentina Alda Carozzi, Virginia Rodriguez-Menendez, Eleonora Pozzi, Annalisa Canta, Alessia Chiorazzi, Elisa Ballarini, Paola Alberti, Cristina Meregalli, Nicoletta Cordani, Erika Donà, Daniele Ramazzotti, Alberto Bravin, Giuliana Tromba, Guido Cavaletti, Antonio Giuliano Zippo, Carozzi, V, Rodriguez-Menendez, V, Pozzi, E, Canta, A, Chiorazzi, A, Ballarini, E, Alberti, P, Meregalli, C, Cordani, N, Donà, E, Ramazzotti, D, Bravin, A, Tromba, G, Cavaletti, G, Giuliano Zippo, A, Valentina Alda Carozzi, Virginia Rodriguez-Menendez, Eleonora Pozzi, Annalisa Canta, Alessia Chiorazzi, Elisa Ballarini, Paola Alberti, Cristina Meregalli, Nicoletta Cordani, Erika Donà, Daniele Ramazzotti, Alberto Bravin, Giuliana Tromba, Guido Cavaletti, and Antonio Giuliano Zippo
Abstract: Chemotherapy-induced painful peripheral neurotoxicity (painful-CIPN), with paresthesia, numbness, dysaesthesia, and neuropathic pain ranks among the most common dose-limiting toxicity of widely used anticancer drugs. Beside peripheral neurons, for several years considered the only reasonable target for painful-CIPN study, the recent evaluation of the microvascular angiogenesis in the somatosensory pathway, reveals other important actors in the neuropathic pain development and chronicization. To elucidate the relation between chemotherapy-induced neuropathic pain and vascular alterations, we evaluated the microvasculature in central and peripheral nervous compartments of rats exposed to neurotoxic chemotherapy. Rats were treated with paclitaxel 10 mg/kg once a week for 4 weeks, or with cisplatin 2mg/kg twice a week for 4 weeks or with their vehicles. Animals were tested for neurophysiological abnormalities and pain before and after the treatments. Post-mortem samples were analyzed at synchrotron radiation sources by X-ray Phase-Contrast Tomography (XPCT) Imaging and processed for quantitative and morphological analyses of microvascular structures. Complementarily, histochemical and molecular evaluations were performed to validate the results. XPCT analysis revealed that rats exposed to paclitaxel (affected by a painful sensory axonopathy) showed an increased vascular density (putative sprouting angiogenesis) in the crucial districts of the central (somatosensory cortex and lumbar spinal cord) and peripheral nervous system (lumbar Dorsal Root Ganglia and peripheral nerves). However, the complexity of the vascular network and the size of neo-formed vessels were significantly decreased in some specific regions. On the other hand, no significant changes were observed in rats exposed to CDDP (affected by a painless mild neuronopathy) suggesting a specific involvement of neo-angiogenesis in the development of neuropathic pain. Molecular analysis performed on the DRG and S1
Published: 2024

10. Repurposing chemotherapy-induced peripheral neuropathy grading

Author: Velasco, R, Argyriou, A, Cornblath, D, Bruna, P, Alberti, P, Rossi, E, Merkies, I, Psimaras, D, Briani, C, Lalisang, R, Schenone, A, Cavaletti, G, Bruna, J, Velasco, Roser, Argyriou, Andreas A, Cornblath, David R, Bruna, Pere, Alberti, Paola, Rossi, Emanuela, Merkies, Ingemar S J, Psimaras, Dimitri, Briani, Chiara, Lalisang, Roy I, Schenone, Angelo, Cavaletti, Guido, Bruna, Jordi, Velasco, R, Argyriou, A, Cornblath, D, Bruna, P, Alberti, P, Rossi, E, Merkies, I, Psimaras, D, Briani, C, Lalisang, R, Schenone, A, Cavaletti, G, Bruna, J, Velasco, Roser, Argyriou, Andreas A, Cornblath, David R, Bruna, Pere, Alberti, Paola, Rossi, Emanuela, Merkies, Ingemar S J, Psimaras, Dimitri, Briani, Chiara, Lalisang, Roy I, Schenone, Angelo, Cavaletti, Guido, and Bruna, Jordi
Abstract: Background and purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is perceived differently by patients and physicians, complicating its assessment. Current recommendations advocate combining clinical and patient-reported outcomes measures, but this approach can be challenging in patient care. This multicenter European study aims to bridge the gap between patients' perceptions and neurological impairments by aligning both perspectives to improve treatment decision-making. Methods: Data were pooled from two prospective studies of subjects (n = 372) with established CIPN. Patient and physician views regarding CIPN were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Total Neuropathy Scale-clinical version (TNSc) items, and the disease-specific quality of life - Chemotherapy-Induced Peripheral Neuropathy questionnaire (QLQ-CIPN20) from the European Organization for Research and Treatment of Cancer (EORTC). To identify inherent neurotoxic severity patterns, we employed hierarchical cluster analysis optimized with k-means clustering and internally validated by discriminant functional analysis. Results: Both NCI-CTCAE and TNSc demonstrated a significant difference in the distribution of severity grades in relation to QLQ-CIPN20 scores. However, a proportion of subjects with different neurotoxic severity grades exhibited overlapping QLQ-CIPN20 scores. We identified three distinct clusters classifying subjects as having severely impaired, intermediately impaired, and mildly impaired CIPN based on TNSc and QLQ-CIPN20 scores. No differences in demographics, cancer type distribution, or class of drug received were observed. Conclusions: Our results confirm the heterogeneity in CIPN perception between patients and physicians and identify three well-differentiated subgroups of patients delineated by degree of CIPN impairment based on scores derived from TNSc and QLQ-CIPN20. A more refined assessment of CIPN could po
Published: 2024

11. Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice

Author: Li, Y, Kazuki, Y, Drabison, T, Kobayashi, K, Fujita, K, Xu, Y, Jin, Y, Ahmed, E, Li, J, Eisenmann, E, Baker, S, Cavaletti, G, Sparreboom, A, Hu, S, Li, Yang, Kazuki, Yasuhiro, Drabison, Thomas, Kobayashi, Kaoru, Fujita, Ken-Ichi, Xu, Yue, Jin, Yan, Ahmed, Eman, Li, Junan, Eisenmann, Eric D, Baker, Sharyn D, Cavaletti, Guido, Sparreboom, Alex, Hu, Shuiying, Li, Y, Kazuki, Y, Drabison, T, Kobayashi, K, Fujita, K, Xu, Y, Jin, Y, Ahmed, E, Li, J, Eisenmann, E, Baker, S, Cavaletti, G, Sparreboom, A, Hu, S, Li, Yang, Kazuki, Yasuhiro, Drabison, Thomas, Kobayashi, Kaoru, Fujita, Ken-Ichi, Xu, Yue, Jin, Yan, Ahmed, Eman, Li, Junan, Eisenmann, Eric D, Baker, Sharyn D, Cavaletti, Guido, Sparreboom, Alex, and Hu, Shuiying
Abstract: Previous studies have suggested that the incidence of vincristine-induced peripheral neuropathy (VIPN) is potentially linked with cytochrome P450 (CYP)3A5, a polymorphic enzyme that metabolizes vincristine in vitro, and with concurrent use of azole antifungals such as ketoconazole. The assumed mechanism for these interactions is through modulation of CYP3A-mediated metabolism, leading to decreased vincristine clearance and increased susceptibility to VIPN. Given the controversy surrounding the contribution of these mechanisms, we directly tested these hypotheses in genetically engineered mouse models with a deficiency of the entire murine Cyp3a locus [Cyp3a(2/2) mice] and in humanized transgenic animals with hepatic expression of functional and nonfunctional human CYP3A5 variants. Compared with wild-type mice, the systemic exposure to vincristine was increased by only 1.15-fold (95% confidence interval, 0.84–1.58) in Cyp3a(2/2) mice, suggesting that the clearance of vincristine in mice is largely independent of hepatic Cyp3a function. In line with these observations, we found that Cyp3a deficiency or pretreatment with the CYP3A inhibitors ketoconazole or nilotinib did not influence the severity and time course of VIPN and that exposure to vincristine was not substantially altered in humanized CYP3A5*3 mice or humanized CYP3A5*1 mice compared with Cyp3a(2/2) mice. Our study suggests that the contribution of CYP3A5-mediated metabolism to vincristine elimination and the associated drug–drug interaction potential is limited and that plasma levels of vincristine are unlikely to be strongly predictive of VIPN. SIGNIFICANCE STATEMENT The current study suggests that CYP3A5 genotype status does not substantially influence vincristine disposition and neurotoxicity in translationally relevant murine models. These findings raise concerns about the causality of previously reported relationships between variant CYP3A5 genotypes or concomitant azole use with the incidence of vincr
Published: 2024

12. Molsidomine provides neuroprotection against vincristine-induced peripheral neurotoxicity through soluble guanylyl cyclase activation

Author: Utkina-Sosunova, I, Chiorazzi, A, de Planell-Saguer, M, Li, H, Meregalli, C, Pozzi, E, Carozzi, V, Canta, A, Monza, L, Alberti, P, Fumagalli, G, Karan, C, Moayedi, Y, Przedborski, S, Cavaletti, G, Lotti, F, Utkina-Sosunova, Irina, Chiorazzi, Alessia, de Planell-Saguer, Mariangels, Li, Hai, Meregalli, Cristina, Pozzi, Eleonora, Carozzi, Valentina Alda, Canta, Annalisa, Monza, Laura, Alberti, Paola, Fumagalli, Giulia, Karan, Charles, Moayedi, Yalda, Przedborski, Serge, Cavaletti, Guido, Lotti, Francesco, Utkina-Sosunova, I, Chiorazzi, A, de Planell-Saguer, M, Li, H, Meregalli, C, Pozzi, E, Carozzi, V, Canta, A, Monza, L, Alberti, P, Fumagalli, G, Karan, C, Moayedi, Y, Przedborski, S, Cavaletti, G, Lotti, F, Utkina-Sosunova, Irina, Chiorazzi, Alessia, de Planell-Saguer, Mariangels, Li, Hai, Meregalli, Cristina, Pozzi, Eleonora, Carozzi, Valentina Alda, Canta, Annalisa, Monza, Laura, Alberti, Paola, Fumagalli, Giulia, Karan, Charles, Moayedi, Yalda, Przedborski, Serge, Cavaletti, Guido, and Lotti, Francesco
Abstract: Peripheral neurotoxicity is a dose-limiting adverse reaction of primary frontline chemotherapeutic agents, including vincristine. Neuropathy can be so disabling that patients drop out of potentially curative therapy, negatively impacting cancer prognosis. The hallmark of vincristine neurotoxicity is axonopathy, yet its underpinning mechanisms remain uncertain. We developed a comprehensive drug discovery platform to identify neuroprotective agents against vincristine-induced neurotoxicity. Among the hits identified, SIN-1-an active metabolite of molsidomine-prevents vincristine-induced axonopathy in both motor and sensory neurons without compromising vincristine anticancer efficacy. Mechanistically, we found that SIN-1's neuroprotective effect is mediated by activating soluble guanylyl cyclase. We modeled vincristine-induced peripheral neurotoxicity in rats to determine molsidomine therapeutic potential in vivo. Vincristine administration induced severe nerve damage and mechanical hypersensitivity that were attenuated by concomitant treatment with molsidomine. This study provides evidence of the neuroprotective properties of molsidomine and warrants further investigations of this drug as a therapy for vincristine-induced peripheral neurotoxicity.
Published: 2024

13. 3D Digital tools in human anatomy teaching from peer-to-peer tutoring to clinically oriented approaches: a single center experience.

Author: Alberti, P, Cavaletti, G, Alberti, P, and Cavaletti, G
Published: 2024

14. Translation of paclitaxel-induced peripheral neurotoxicity from mice to patients: the importance of model selection

Author: Cavaletti, G, Alberti, P, Canta, A, Carozzi, V, Cherchi, L, Chiorazzi, A, Crippa, L, Marmiroli, P, Meregalli, C, Pozzi, E, Rodriguez-Menendez, V, Steinkühler, C, Licandro, S, Cavaletti, Guido, Alberti, Paola, Canta, Annalisa, Carozzi, Valentina, Cherchi, Laura, Chiorazzi, Alessia, Crippa, Luca, Marmiroli, Paola, Meregalli, Cristina, Pozzi, Eleonora, Rodriguez-Menendez, Virginia, Steinkühler, Christian, Licandro, Simonetta Andrea, Cavaletti, G, Alberti, P, Canta, A, Carozzi, V, Cherchi, L, Chiorazzi, A, Crippa, L, Marmiroli, P, Meregalli, C, Pozzi, E, Rodriguez-Menendez, V, Steinkühler, C, Licandro, S, Cavaletti, Guido, Alberti, Paola, Canta, Annalisa, Carozzi, Valentina, Cherchi, Laura, Chiorazzi, Alessia, Crippa, Luca, Marmiroli, Paola, Meregalli, Cristina, Pozzi, Eleonora, Rodriguez-Menendez, Virginia, Steinkühler, Christian, and Licandro, Simonetta Andrea
Abstract: Paclitaxel-induced peripheral neurotoxicity (PIPN) is a potentially dose-limiting side effect in anticancer chemotherapy. Several animal models of PIPN exist, but their results are sometimes difficult to be translated into the clinical setting. We compared 2 widely used PIPN models characterized by marked differences in their methodologies. Female C57BL/6JOlaHsd mice were used, and they received only paclitaxel vehicle (n = 38) or paclitaxel via intravenous injection (n = 19, 70 mg/kg) once a week for 4 weeks (Study 1) or intraperitoneally (n = 19, 10 mg/kg) every 2 days for 7 times (Study 2). At the end of treatment and in the follow-up, mice underwent behavioral and neurophysiological assessments of PIPN. At the same time points, some mice were killed and dorsal root ganglia, skin, and sciatic and caudal nerve samples underwent pathological examination. Serum neurofilament light levels were also measured. The differences in the neurotoxicity parameters were analyzed using a nonparametric Mann-Whitney test, with significance level set at P < 0.05. Study 1 showed significant and consistent behavioral, neurophysiological, pathological, and serological changes induced by paclitaxel administration at the end of treatment, and most of these changes were still evident in the follow-up period. By contrast, study 2 evidenced only a transient small fiber neuropathy, associated with neuropathic pain. Our comparative study clearly distinguished a PIPN model recapitulating all the clinical features of the human condition and a model showing only small fiber neuropathy with neuropathic pain induced by paclitaxel.
Published: 2024

15. NEUROINFLAMMATION AS A POTENTIAL TARGET FOR CIPN DIAGNOSTIC AND TREATMENT

Author: Tarasiuk, O, Pozzi, E, Canta, A, Chiorazzi, A, Carozzi, V, Ballarini, E, Rodriguez-Menendez, V, Argentini, A, Foti, M, Cavaletti, G, Meregalli, C, Canta A, Tarasiuk, O, Pozzi, E, Canta, A, Chiorazzi, A, Carozzi, V, Ballarini, E, Rodriguez-Menendez, V, Argentini, A, Foti, M, Cavaletti, G, Meregalli, C, and Canta A
Published: 2024

16. Histone deacetylase 6 inhibitors and neuroprotection: evidences and molecular mechanisms

Author: Squarzoni, A, Donzelli, E, Rodriguez-Menendez, V, Cavaletti, G, Scuteri, A, Squarzoni, A, Donzelli, E, Rodriguez-Menendez, V, Cavaletti, G, and Scuteri, A
Published: 2024

17. Dorsal Root Ganglia Neurons Morphometry Analysing Method Optimization

Author: Invernizzi, C, Capelli, C, Pozzi, E, Canta, A, Chiorazzi, A, Ballarini, E, Rodriguez Menendez, V, Cavaletti, G, Alberti, P, Alberti P, Invernizzi, C, Capelli, C, Pozzi, E, Canta, A, Chiorazzi, A, Ballarini, E, Rodriguez Menendez, V, Cavaletti, G, Alberti, P, and Alberti P
Published: 2024

18. EVALUATION OF SATELLITE GLIAL CELLS CHANGES IN DORSAL ROOT GANGLIA IN CHEMOTHERAPY-INDUCED NEUROTOXICITY MODELS

Author: Pozzi, E, Rodriguez-Menendez, V, Argentini, A, Canta, A, Alberti, P, Meregalli, C, Cherchi, L, Cavaletti, G, Carozzi, V, Carozzi VA, Pozzi, E, Rodriguez-Menendez, V, Argentini, A, Canta, A, Alberti, P, Meregalli, C, Cherchi, L, Cavaletti, G, Carozzi, V, and Carozzi VA
Published: 2024

19. Proteasome inhibitors-based chemotherapy induced neurotoxicity: focus on cytoskeleton and mitochondrial dysfunction

Author: Malacrida, A, Tarasiuk, O, Rodriguez-Menendez, V, Stanga, S, Pero, M, Bartolini, F, Nicolini, G, Cavaletti, G, Meregalli, C, Pero, ME, Malacrida, A, Tarasiuk, O, Rodriguez-Menendez, V, Stanga, S, Pero, M, Bartolini, F, Nicolini, G, Cavaletti, G, Meregalli, C, and Pero, ME
Abstract: The proteasomal system is involved in the turnover of damaged proteins and it is responsible for their degradation. Because of its role in oncogenesis, the inhibition of the proteasome system is a promising therapeutic target for neoplastic treatment. The accumulation and deleterious effects of toxic proteins are frequently induced by exposure to chemotherapeutic drugs and 20S proteasome inhibitors, such as bortezomib (BTZ) and carfilzomib (CFZ) have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM) and some other liquid tumours. Although the survival of MM patients has been improved by the introduction of both drugs-based therapies, these proteasome inhibitors have several limitations, including chemotherapy-induced peripheral neurotoxicity (CIPN). Since it is becoming increasingly clear that cytoskeletal integrity and mitochondrial function are intricately linked, we compared these targets after BTZ and CFZ treatments in vitro. Primary culture of dorsal root ganglion (DRG) sensory neurons isolated from adult mice were treated with BTZ 10 nM and CFZ 60 nM for 24 hours, and measurement of energy metabolism were investigated using XFe24 Seahorse Analyzer, while a morphological analysis of mitochondria was performed in silico using the toolset MiNA (Mitochondrial Network Analysis). Moreover, by immunoblotting we have evaluated drug-induced alterations of proteins involved in cytoskeleton, mitochondrial oxidative phosphorylation, and molecular motors transport. BTZ was shown to induce several cytoskeletal damage in terms of increased levels of delta2-tubulin, acetylated tubulin and MAP2 expressions compared to both CFZ-treated cells and untreated cells. Conversely, the evaluation of the bioenergetic mitochondrial metabolism revealed a reduction in basal and maximal respiration for both chemotherapeutic drugs. Similarly, both BTZ-and CFZ cultures showed a decrease in ATP production compared with the untreated cells.
Published: 2024

20. Oxaliplatin-induced peripheral neurotoxicity: molecular insights

Author: Alberti, P, Pozzi, E, Serra, M, Trucas, M, Boi, M, Capelli, C, Invernizzi, C, Chiorazzi, A, Ballarini, E, Rodriguez-Menendez, V, Quartu, M, Cavaletti, G, Serra, MP, Alberti, P, Pozzi, E, Serra, M, Trucas, M, Boi, M, Capelli, C, Invernizzi, C, Chiorazzi, A, Ballarini, E, Rodriguez-Menendez, V, Quartu, M, Cavaletti, G, and Serra, MP
Published: 2024

21. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up

Author: Jordan, B., Margulies, A., Cardoso, F., Cavaletti, G., Haugnes, H.S., Jahn, P., Le Rhun, E., Preusser, M., Scotté, F., Taphoorn, M.J.B., and Jordan, K.
Published: 2020
Full Text: View/download PDF

22. Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect

Author: Malacrida, A., Semperboni, S., Di Domizio, A., Palmioli, A., Broggi, L., Airoldi, C., Meregalli, C., Cavaletti, G., and Nicolini, G.
Published: 2021
Full Text: View/download PDF

23. Role of Mouse Organic Cation Transporter 2 for Nephro- and Peripheral Neurotoxicity Induced by Chemotherapeutic Treatment with Cisplatin

Author: Hucke, A, Schröter, R, Ceresa, C, Chiorazzi, A, Canta, A, Semperboni, S, Marmiroli, P, Cavaletti, G, Gess, B, Ciarimboli, G, Hucke A., Schröter R., Ceresa C., Chiorazzi A., Canta A., Semperboni S., Marmiroli P., Cavaletti G., Gess B., Ciarimboli G., Hucke, A, Schröter, R, Ceresa, C, Chiorazzi, A, Canta, A, Semperboni, S, Marmiroli, P, Cavaletti, G, Gess, B, Ciarimboli, G, Hucke A., Schröter R., Ceresa C., Chiorazzi A., Canta A., Semperboni S., Marmiroli P., Cavaletti G., Gess B., and Ciarimboli G.
Abstract: Cisplatin (CDDP) is an efficient chemotherapeutic agent broadly used to treat solid cancers. Chemotherapy with CDDP can cause significant unwanted side effects such as renal toxicity and peripheral neurotoxicity. CDDP is a substrate of organic cation transporters (OCT), transporters that are highly expressed in renal tissue. Therefore, CDDP uptake by OCT may play a role in causing unwanted toxicities of CDDP anticancer treatment. In this study, the contribution of the mouse OCT2 (mOCT2) to CDDP nephro- and peripheral neurotoxicity was investigated by comparing the effects of cyclic treatment with low doses of CDDP on renal and neurological functions in wild-type (WT) mice and mice with genetic deletion of OCT2 (OCT2−/− mice). This CDDP treatment protocol caused significant impairment of kidneys and peripherical neurological functions in WT mice. These effects were significantly reduced in OCT2−/− mice, however, less profoundly than what was previously measured in mice with genetic deletion of both OCT1 and 2 (OCT1-2−/− mice). Comparing the apparent affinities (IC50) of mOCT1 and mOCT2 for CDDP, the mOCT1 displayed a higher affinity for CDDP than the mOCT2 (IC50: 9 and 558 µM, respectively). Also, cellular toxicity induced by incubation with 100 µM CDDP was more pronounced in cells stably expressing mOCT1 than in cells expressing mOCT2. Therefore, in mice, CDDP uptake by both OCT1 and 2 contributes to the development of CDDP undesired side effects. OCT seem to be suitable targets for establishing treatment protocols aimed at decreasing unwanted CDDP toxicity and improving anticancer treatment with CDDP.
Published: 2023

24. Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy

Author: Doneddu, P, Akyil, H, Manganelli, F, Briani, C, Cocito, D, Benedetti, L, Mazzeo, A, Fazio, R, Filosto, M, Cosentino, G, Di Stefano, V, Antonini, G, Marfia, G, Inghilleri, M, Siciliano, G, Clerici, A, Carpo, M, Schenone, A, Luigetti, M, Lauria, G, Mata, S, Rosso, T, Minicuci, G, Lucchetta, M, Cavaletti, G, Liberatore, G, Spina, E, Campagnolo, M, Peci, E, Germano, F, Gentile, L, Strano, C, Cotti Piccinelli, S, Vegezzi, E, Leonardi, L, Mataluni, G, Ceccanti, M, Schirinzi, E, Romozzi, M, Nobile-Orazio, E, Doneddu P. E., Akyil H., Manganelli F., Briani C., Cocito D., Benedetti L., Mazzeo A., Fazio R., Filosto M., Cosentino G., Di Stefano V., Antonini G., Marfia G. A., Inghilleri M., Siciliano G., Clerici A. M., Carpo M., Schenone A., Luigetti M., Lauria G., Mata S., Rosso T., Minicuci G. M., Lucchetta M., Cavaletti G., Liberatore G., Spina E., Campagnolo M., Peci E., Germano F., Gentile L., Strano C., Cotti Piccinelli S., Vegezzi E., Leonardi L., Mataluni G., Ceccanti M., Schirinzi E., Romozzi M., Nobile-Orazio E., Doneddu, P, Akyil, H, Manganelli, F, Briani, C, Cocito, D, Benedetti, L, Mazzeo, A, Fazio, R, Filosto, M, Cosentino, G, Di Stefano, V, Antonini, G, Marfia, G, Inghilleri, M, Siciliano, G, Clerici, A, Carpo, M, Schenone, A, Luigetti, M, Lauria, G, Mata, S, Rosso, T, Minicuci, G, Lucchetta, M, Cavaletti, G, Liberatore, G, Spina, E, Campagnolo, M, Peci, E, Germano, F, Gentile, L, Strano, C, Cotti Piccinelli, S, Vegezzi, E, Leonardi, L, Mataluni, G, Ceccanti, M, Schirinzi, E, Romozzi, M, Nobile-Orazio, E, Doneddu P. E., Akyil H., Manganelli F., Briani C., Cocito D., Benedetti L., Mazzeo A., Fazio R., Filosto M., Cosentino G., Di Stefano V., Antonini G., Marfia G. A., Inghilleri M., Siciliano G., Clerici A. M., Carpo M., Schenone A., Luigetti M., Lauria G., Mata S., Rosso T., Minicuci G. M., Lucchetta M., Cavaletti G., Liberatore G., Spina E., Campagnolo M., Peci E., Germano F., Gentile L., Strano C., Cotti Piccinelli S., Vegezzi E., Leonardi L., Mataluni G., Ceccanti M., Schirinzi E., Romozzi M., and Nobile-Orazio E.
Abstract: Background To assess the ability of the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) clinical criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) to include within their classification the whole spectrum of clinical heterogeneity of the disease and to define the clinical characteristics of the unclassifiable clinical forms. Methods The 2021 EAN/PNS clinical criteria for CIDP were applied to 329 patients fulfilling the electrodiagnostic (and in some cases also the supportive) criteria for the diagnosis of CIDP. Clinical characteristics were reviewed for each patient not strictly fulfilling the clinical criteria ('unclassifiable'). Results At study inclusion, 124 (37.5%) patients had an unclassifiable clinical presentation, including 110 (89%) with a typical CIDP-like clinical phenotype in whom some segments of the four limbs were unaffected by weakness ('incomplete typical CIDP'), 10 (8%) with a mild distal, symmetric, sensory or sensorimotor polyneuropathy confined to the lower limbs with cranial nerve involvement ('cranial nerve predominant CIDP') and 4 (1%) with a symmetric sensorimotor polyneuropathy limited to the proximal and distal areas of the lower limbs ('paraparetic CIDP'). Eighty-one (65%) patients maintained an unclassifiable presentation during the entire disease follow-up while 13 patients progressed to typical CIDP. Patients with the unclassifiable clinical forms compared with patients with typical CIDP had a milder form of CIDP, while there was no difference in the distribution patterns of demyelination. Conclusions A proportion of patients with CIDP do not strictly fulfil the 2021 EAN/PNS clinical criteria for diagnosis. These unclassifiable clinical phenotypes may pose diagnostic challenges and thus deserve more attention in clinical practice and research.
Published: 2023

25. Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials

Author: Schilke, E, Remoli, G, Funelli, E, Galimberti, M, Fusco, M, Cereda, D, Balducci, C, Frigo, M, Cavaletti, G, Schilke E. D., Remoli G., Funelli E., Galimberti M., Fusco M. L., Cereda D., Balducci C., Frigo M., Cavaletti G., Schilke, E, Remoli, G, Funelli, E, Galimberti, M, Fusco, M, Cereda, D, Balducci, C, Frigo, M, Cavaletti, G, Schilke E. D., Remoli G., Funelli E., Galimberti M., Fusco M. L., Cereda D., Balducci C., Frigo M., and Cavaletti G.
Abstract: The present study aims to describe the state of the art of fluid biomarkers use in ongoing multiple sclerosis (MS) clinical trials. A review of 608 ongoing protocols in the clinicaltrials.gov and EudraCT databases was performed. The trials enrolled patients with a diagnosis of relapsing remitting MS, secondary progressive MS, and/or primary progressive MS according to Revised McDonald criteria or relapsing MS according to Lublin et al. (2014). The presence of fluid biomarkers among the primary and/or secondary study outcomes was assessed. Overall, 5% of ongoing interventional studies on MS adopted fluid biomarkers. They were mostly used as secondary outcomes in phase 3–4 clinical trials to support the potential disease-modifying properties of the intervention. Most studies evaluated neurofilament light chains (NfLs). A small number considered other novel fluid biomarkers of neuroinflammation and neurodegeneration such as glial fibrillary acid protein (GFAP). Considering the numerous ongoing clinical trials in MS, still a small number adopted fluid biomarkers as outcome measures, thus testifying the distance from clinical practice. In most protocols, fluid biomarkers were used to evaluate the effectiveness of approved second-line therapies, but also, new drugs (particularly Bruton kinase inhibitors). NfLs were also adopted to monitor disease progression after natalizumab suspension in stable patients, cladribine efficacy after anti-CD20 discontinuation, and the efficacy of autologous hematopoietic stem cell transplant (AHSCT) compared to medical treatment. Nevertheless, further validation studies are needed for all considered fluid biomarkers to access clinical practice, and cost-effectiveness in the “real word” remains to be clarified.
Published: 2023

26. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

Author: Iaffaldano, P, Lucisano, G, Guerra, T, Patti, F, Cocco, E, De Luca, G, Brescia Morra, V, Pozzilli, C, Zaffaroni, M, Ferraro, D, Gasperini, C, Salemi, G, Bergamaschi, R, Lus, G, Inglese, M, Romano, S, Bellantonio, P, Di Monte, E, Maniscalco, G, Conte, A, Lugaresi, A, Vianello, M, Torri Clerici, V, Di Sapio, A, Pesci, I, Granella, F, Totaro, R, Marfia, G, Danni, M, Cavalla, P, Valentino, P, Aguglia, U, Montepietra, S, Ferraro, E, Protti, A, Spitaleri, D, Avolio, C, De Riz, M, Maimone, D, Cavaletti, G, Gazzola, P, Tedeschi, G, Sessa, M, Rovaris, M, Di Palma, F, Gatto, M, Cargnelutti, D, De Robertis̄, F, Logullo, F, Rini, A, Meucci, G, Ardito, B, Banfi, P, Nasuelli, D, Paolicelli, D, Rocca, M, Portaccio, E, Chisari, C, Fenu, G, Onofrj, M, Carotenuto, A, Ruggieri, S, Tortorella, C, Ragonese, P, Nica, M, Amato, M, Filippi, M, Trojano, M, Iaffaldano P., Lucisano G., Guerra T., Patti F., Cocco E., De Luca G., Brescia Morra V., Pozzilli C., Zaffaroni M., Ferraro D., Gasperini C., Salemi G., Bergamaschi R., Lus G., Inglese M., Romano S., Bellantonio P., Di Monte E., Maniscalco G. T., Conte A., Lugaresi A., Vianello M., Torri Clerici V. L. A., Di Sapio A., Pesci I., Granella F., Totaro R., Marfia G. A., Danni M. C., Cavalla P., Valentino P., Aguglia U., Montepietra S., Ferraro E., Protti A., Spitaleri D., Avolio C., De Riz M., Maimone D., Cavaletti G., Gazzola P., Tedeschi G., Sessa M., Rovaris M., Di Palma F., Gatto M., Cargnelutti D., De Robertis̄ F., Logullo F. O., Rini A., Meucci G., Ardito B., Banfi P., Nasuelli D., Paolicelli D., Rocca M. A., Portaccio E., Chisari C. G., Fenu G., Onofrj M., Carotenuto A., Ruggieri S., Tortorella C., Ragonese P., Nica M., Amato M. P., Filippi M., Trojano M., Iaffaldano, P, Lucisano, G, Guerra, T, Patti, F, Cocco, E, De Luca, G, Brescia Morra, V, Pozzilli, C, Zaffaroni, M, Ferraro, D, Gasperini, C, Salemi, G, Bergamaschi, R, Lus, G, Inglese, M, Romano, S, Bellantonio, P, Di Monte, E, Maniscalco, G, Conte, A, Lugaresi, A, Vianello, M, Torri Clerici, V, Di Sapio, A, Pesci, I, Granella, F, Totaro, R, Marfia, G, Danni, M, Cavalla, P, Valentino, P, Aguglia, U, Montepietra, S, Ferraro, E, Protti, A, Spitaleri, D, Avolio, C, De Riz, M, Maimone, D, Cavaletti, G, Gazzola, P, Tedeschi, G, Sessa, M, Rovaris, M, Di Palma, F, Gatto, M, Cargnelutti, D, De Robertis̄, F, Logullo, F, Rini, A, Meucci, G, Ardito, B, Banfi, P, Nasuelli, D, Paolicelli, D, Rocca, M, Portaccio, E, Chisari, C, Fenu, G, Onofrj, M, Carotenuto, A, Ruggieri, S, Tortorella, C, Ragonese, P, Nica, M, Amato, M, Filippi, M, Trojano, M, Iaffaldano P., Lucisano G., Guerra T., Patti F., Cocco E., De Luca G., Brescia Morra V., Pozzilli C., Zaffaroni M., Ferraro D., Gasperini C., Salemi G., Bergamaschi R., Lus G., Inglese M., Romano S., Bellantonio P., Di Monte E., Maniscalco G. T., Conte A., Lugaresi A., Vianello M., Torri Clerici V. L. A., Di Sapio A., Pesci I., Granella F., Totaro R., Marfia G. A., Danni M. C., Cavalla P., Valentino P., Aguglia U., Montepietra S., Ferraro E., Protti A., Spitaleri D., Avolio C., De Riz M., Maimone D., Cavaletti G., Gazzola P., Tedeschi G., Sessa M., Rovaris M., Di Palma F., Gatto M., Cargnelutti D., De Robertis̄ F., Logullo F. O., Rini A., Meucci G., Ardito B., Banfi P., Nasuelli D., Paolicelli D., Rocca M. A., Portaccio E., Chisari C. G., Fenu G., Onofrj M., Carotenuto A., Ruggieri S., Tortorella C., Ragonese P., Nica M., Amato M. P., Filippi M., and Trojano M.
Abstract: Background: Active relapsing–remitting (RR) and secondary progressive (SP) multiple sclerosis (MS) are currently defined as “relapsing MS” (RMS). The aim of this cross-sectional study was to assess drivers of treatment switches due to clinical relapses in a population of RMS patients collected in the Italian MS and Related Disorders Register (I-MS&RD). Methods: RRMS and SPMS patients with at least one relapse in a time window of 2 years before of data extraction were defined as RMS. Factors associated with disease-modifying therapy (DMT) switching due to clinical activity were assessed through multivariable logistic regression models in which treatment exposure was included as the last recorded DMT and the last DMT’s class [moderate-efficacy (ME), high-efficacy (HE) DMTs and anti-CD20 drugs]. Results: A cohort of 4739 RMS patients (4161 RRMS, 578 SPMS) was extracted from the I-MS&RD. A total of 2694 patients switching DMTs due to relapses were identified. Switchers were significantly (p < 0.0001) younger, less disabled, more frequently affected by an RR disease course in comparison to non-switcher patients. The multivariable logistic regression models showed that Alemtuzumab (OR 0.08, 95% CI 0.02–0.37), Natalizumab (0.48, 0.30–0.76), Ocrelizumab (0.1, 0.02–0.45) and Rituximab (0.23, 0.06–0.82) exposure was a protective factor against treatment switch due to relapses. Moreover, the use of HE DMTs (0.43, 0.31–0.59), especially anti-CD20 drugs (0.14, 0.05–0.37), resulted to be a protective factor against treatment switch due to relapses in comparison with ME DMTs. Conclusions: More than 50% of RMS switched therapy due to disease activity. HE DMTs, especially anti-CD20 drugs, significantly reduce the risk of treatment switch.
Published: 2023

27. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome

Author: Al-Hakem, H, Doets, A, Stino, A, Zivkovic, S, Andersen, H, Willison, H, Cornblath, D, Gorson, K, Islam, Z, Mohammad, Q, Sindrup, S, Kusunoki, S, Davidson, A, Casasnovas, C, Bateman, K, Miller, J, Van Den Berg, B, Verboon, C, Roodbol, J, Leonhard, S, Arends, S, Luijten, L, Benedetti, L, Kuwabara, S, Van Den Bergh, P, Monges, S, Marfia, G, Shahrizaila, N, Galassi, G, Pereon, Y, Burmann, J, Kuitwaard, K, Kleyweg, R, Marchesoni, C, Tous, M, Querol, L, Martin-Aguilar, L, Wang, Y, Nobile-Orazio, E, Rinaldi, S, Schenone, A, Pardo, J, Vermeij, F, Waheed, W, Lehmann, H, Granit, V, Stein, B, Cavaletti, G, Gutierrez-Gutierrez, G, Barroso, F, Visser, L, Katzberg, H, Dardiotis, E, Attarian, S, Van Der Kooi, A, Eftimov, F, Wirtz, P, Samijn, J, Jacobus Gilhuis, H, Hadden, R, Holt, J, Sheikh, K, Kolb, N, Karafiath, S, Vytopil, M, Antonini, G, Feasby, T, Faber, C, Kramers, H, Busby, M, Roberts, R, Silvestri, N, Fazio, R, Van Dijk, G, Garssen, M, Verschuuren, J, Harbo, T, Jacobs, B, Al-Hakem H., Doets A. Y., Stino A. M., Zivkovic S. A., Andersen H., Willison H. J., Cornblath D. R., Gorson K. C., Islam Z., Mohammad Q. D., Sindrup So. H., Kusunoki S., Davidson A., Casasnovas C., Bateman K., Miller J. A. L., Van Den Berg B., Verboon C., Roodbol J., Leonhard S. E., Arends S., Luijten L. W. G., Benedetti L., Kuwabara S., Van Den Bergh P., Monges S., Marfia G. A., Shahrizaila N., Galassi G., Pereon Y., Burmann J., Kuitwaard K., Kleyweg R. P., Marchesoni C., Tous M. J. S., Querol L., Martin-Aguilar L., Wang Y., Nobile-Orazio E., Rinaldi S., Schenone A., Pardo J., Vermeij F. H., Waheed W., Lehmann H. C., Granit V., Stein B., Cavaletti G., Gutierrez-Gutierrez G., Barroso F. A., Visser L. H., Katzberg H. D., Dardiotis E., Attarian S., Van Der Kooi A. J., Eftimov F., Wirtz P. W., Samijn J. P. A., Jacobus Gilhuis H., Hadden R. D. M., Holt J. K. L., Sheikh K. A., Kolb N., Karafiath S., Vytopil M., Antonini G., Feasby T. E., Faber C., Kramers H., Busby M., Roberts R. C., Silvestri N. J., Fazio R., Van Dijk G. W., Garssen M. P. J., Verschuuren J., Harbo T., Jacobs B. C., Al-Hakem, H, Doets, A, Stino, A, Zivkovic, S, Andersen, H, Willison, H, Cornblath, D, Gorson, K, Islam, Z, Mohammad, Q, Sindrup, S, Kusunoki, S, Davidson, A, Casasnovas, C, Bateman, K, Miller, J, Van Den Berg, B, Verboon, C, Roodbol, J, Leonhard, S, Arends, S, Luijten, L, Benedetti, L, Kuwabara, S, Van Den Bergh, P, Monges, S, Marfia, G, Shahrizaila, N, Galassi, G, Pereon, Y, Burmann, J, Kuitwaard, K, Kleyweg, R, Marchesoni, C, Tous, M, Querol, L, Martin-Aguilar, L, Wang, Y, Nobile-Orazio, E, Rinaldi, S, Schenone, A, Pardo, J, Vermeij, F, Waheed, W, Lehmann, H, Granit, V, Stein, B, Cavaletti, G, Gutierrez-Gutierrez, G, Barroso, F, Visser, L, Katzberg, H, Dardiotis, E, Attarian, S, Van Der Kooi, A, Eftimov, F, Wirtz, P, Samijn, J, Jacobus Gilhuis, H, Hadden, R, Holt, J, Sheikh, K, Kolb, N, Karafiath, S, Vytopil, M, Antonini, G, Feasby, T, Faber, C, Kramers, H, Busby, M, Roberts, R, Silvestri, N, Fazio, R, Van Dijk, G, Garssen, M, Verschuuren, J, Harbo, T, Jacobs, B, Al-Hakem H., Doets A. Y., Stino A. M., Zivkovic S. A., Andersen H., Willison H. J., Cornblath D. R., Gorson K. C., Islam Z., Mohammad Q. D., Sindrup So. H., Kusunoki S., Davidson A., Casasnovas C., Bateman K., Miller J. A. L., Van Den Berg B., Verboon C., Roodbol J., Leonhard S. E., Arends S., Luijten L. W. G., Benedetti L., Kuwabara S., Van Den Bergh P., Monges S., Marfia G. A., Shahrizaila N., Galassi G., Pereon Y., Burmann J., Kuitwaard K., Kleyweg R. P., Marchesoni C., Tous M. J. S., Querol L., Martin-Aguilar L., Wang Y., Nobile-Orazio E., Rinaldi S., Schenone A., Pardo J., Vermeij F. H., Waheed W., Lehmann H. C., Granit V., Stein B., Cavaletti G., Gutierrez-Gutierrez G., Barroso F. A., Visser L. H., Katzberg H. D., Dardiotis E., Attarian S., Van Der Kooi A. J., Eftimov F., Wirtz P. W., Samijn J. P. A., Jacobus Gilhuis H., Hadden R. D. M., Holt J. K. L., Sheikh K. A., Kolb N., Karafiath S., Vytopil M., Antonini G., Feasby T. E., Faber C., Kramers H., Busby M., Roberts R. C., Silvestri N. J., Fazio R., Van Dijk G. W., Garssen M. P. J., Verschuuren J., Harbo T., and Jacobs B. C.
Abstract: Background and ObjectivesTo investigate CSF findings in relation to clinical and electrodiagnostic subtypes, severity, and outcome of Guillain-Barré syndrome (GBS) based on 1,500 patients in the International GBS Outcome Study.MethodsAlbuminocytologic dissociation (ACD) was defined as an increased protein level (>0.45 g/L) in the absence of elevated white cell count (<50 cells/L). We excluded 124 (8%) patients because of other diagnoses, protocol violation, or insufficient data. The CSF was examined in 1,231 patients (89%).ResultsIn 846 (70%) patients, CSF examination showed ACD, which increased with time from weakness onset: ≤4 days 57%, >4 days 84%. High CSF protein levels were associated with a demyelinating subtype, proximal or global muscle weakness, and a reduced likelihood of being able to run at week 2 (odds ratio [OR] 0.42, 95% CI 0.25-0.70; p = 0.001) and week 4 (OR 0.44, 95% CI 0.27-0.72; p = 0.001). Patients with the Miller Fisher syndrome, distal predominant weakness, and normal or equivocal nerve conduction studies were more likely to have lower CSF protein levels. CSF cell count was <5 cells/L in 1,005 patients (83%), 5-49 cells/L in 200 patients (16%), and ≥50 cells/L in 13 patients (1%).DiscussionACD is a common finding in GBS, but normal protein levels do not exclude this diagnosis. High CSF protein level is associated with an early severe disease course and a demyelinating subtype. Elevated CSF cell count, rarely ≥50 cells/L, is compatible with GBS after a thorough exclusion of alternative diagnoses.Classification of EvidenceThis study provides Class IV evidence that CSF ACD (defined by the Brighton Collaboration) is common in patients with GBS.
Published: 2023

28. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

Author: Mosconi, P, Guerra, T, Paletta, P, D'Ettorre, A, Ponzio, M, Battaglia, M, Amato, M, Bergamaschi, R, Capobianco, M, Comi, G, Gasperini, C, Patti, F, Pugliatti, M, Ulivelli, M, Trojano, M, Lepore, V, Aguglia, U, Ancona, A, Ardito, B, Avolio, C, Balgera, R, Banfi, P, Barcella, V, Barone, P, Bellantonio, P, Berardinelli, A, Bertora, P, Bianchi, M, Bramanti, P, Brescia Morra, V, Brichetto, G, Brioschi, A, Buccafusca, M, Bucello, S, Busillo, V, Calchetti, B, Cantello, R, Capone, F, Capone, L, Cargnelutti, D, Carozzi, M, Cartechini, E, Cavaletti, G, Cavalla, P, Celani, M, Clerici, R, Clerico, M, Cocco, E, Torri Clerici, V, Coniglio, M, Conte, A, Corea, F, Cottone, S, Crociani, P, D'Andrea, F, Danni, M, De Luca, G, de Pascalis, D, De Riz, M, De Robertis, F, De Rosa, G, De Stefano, N, Della Corte, M, Di Sapio, A, Docimo, R, Falcini, M, Falcone, N, Fermi, S, Ferraro, E, Ferro, M, Fortunato, M, Foschi, M, Gajofatto, A, Gallo, A, Gallo, P, Gatto, M, Gazzola, P, Giordano, A, Granella, F, Grasso, M, Grimaldi, L, Iaffaldano, P, Immovilli, P, Imperiale, D, Inglese, M, Iodice, R, Leva, S, Leuzzi, V, Lugaresi, A, Lus, G, Maimone, D, Mancinelli, L, Maniscalco, G, Marfia, G, Margari, L, Marinelli, F, Marini, B, Marson, A, Mascoli, N, Massacesi, L, Melani, F, Merello, M, Fioretti, C, Mirabella, M, Montepietra, S, Nasuelli, D, Nicolao, P, Pasquali, L, Passantino, F, Pecori, C, Peresson, M, Pesci, I, Piantadosi, C, Piras, M, Pizzorno, M, Plewnia, K, Pozzilli, C, Protti, A, Quatrale, R, Realmuto, S, Ribizzi, G, Rinalduzzi, S, Rini, A, Romano, S, Filippi, M, Ronzoni, M, Rossi, P, Rovaris, M, Salemi, G, Santangelo, G, Santangelo, M, Leone, A, Sarchielli, P, Sinisi, L, Ferraro, D, Solaro, C, Spitaleri, D, Strumia, S, Tassinari, T, Santuccio, G, Tortorella, C, Totaro, R, Tozzo, A, Trivelli, G, Turano, G, Valentino, P, Venturi, S, Vianello, M, Zaffaroni, M, Zarbo, R, Mosconi P., Guerra T., Paletta P., D'Ettorre A., Ponzio M., Battaglia M. A., Amato M. P., Bergamaschi R., Capobianco M., Comi G., Gasperini C., Patti F., Pugliatti M., Ulivelli M., Trojano M., Lepore V., Aguglia U., Amato M., Ancona A., Ardito B., Avolio C., Balgera R., Banfi P., Barcella V., Barone P., Bellantonio P., Berardinelli A., Bertora P., Bianchi M., Bramanti P., Brescia Morra V., Brichetto G., Brioschi A., Buccafusca M., Bucello S., Busillo V., Calchetti B., Cantello R., Capone F., Capone L., Cargnelutti D., Carozzi M., Cartechini E., Cavaletti G., Cavalla P., Celani M., Clerici R., Clerico M., Cocco E., Torri Clerici V., Coniglio M., Conte A., Corea F., Cottone S., Crociani P., D'Andrea F., Danni M., De Luca G., de Pascalis D., De Riz M., De Robertis F., De Rosa G., De Stefano N., Della Corte M., Di Sapio A., Docimo R., Falcini M., Falcone N., Fermi S., Ferraro E., Ferro M., Fortunato M., Foschi M., Gajofatto A., Gallo A., Gallo P., Gatto M., Gazzola P., Giordano A., Granella F., Grasso M., Grimaldi L., Iaffaldano P., Immovilli P., Imperiale D., Inglese M., Iodice R., Leva S., Leuzzi V., Lugaresi A., Lus G., Maimone D., Mancinelli L., Maniscalco G., Marfia G., Margari L., Marinelli F., Marini B., Marson A., Mascoli N., Massacesi L., Melani F., Merello M., Fioretti C., Mirabella M., Montepietra S., Nasuelli D., Nicolao P., Pasquali L., Passantino F., Pecori C., Peresson M., Pesci I., Piantadosi C., Piras M., Pizzorno M., Plewnia K., Pozzilli C., Protti A., Quatrale R., Realmuto S., Ribizzi G., Rinalduzzi S., Rini A., Romano S., Filippi M., Ronzoni M., Rossi P., Rovaris M., Salemi G., Santangelo G., Santangelo M., Leone A., Sarchielli P., Sinisi L., Ferraro D., Solaro C., Spitaleri D., Strumia S., Tassinari T., Santuccio G., Tortorella C., Totaro R., Tozzo A., Trivelli G., Turano G., Valentino P., Venturi S., Vianello M., Zaffaroni M., Zarbo R., Mosconi, P, Guerra, T, Paletta, P, D'Ettorre, A, Ponzio, M, Battaglia, M, Amato, M, Bergamaschi, R, Capobianco, M, Comi, G, Gasperini, C, Patti, F, Pugliatti, M, Ulivelli, M, Trojano, M, Lepore, V, Aguglia, U, Ancona, A, Ardito, B, Avolio, C, Balgera, R, Banfi, P, Barcella, V, Barone, P, Bellantonio, P, Berardinelli, A, Bertora, P, Bianchi, M, Bramanti, P, Brescia Morra, V, Brichetto, G, Brioschi, A, Buccafusca, M, Bucello, S, Busillo, V, Calchetti, B, Cantello, R, Capone, F, Capone, L, Cargnelutti, D, Carozzi, M, Cartechini, E, Cavaletti, G, Cavalla, P, Celani, M, Clerici, R, Clerico, M, Cocco, E, Torri Clerici, V, Coniglio, M, Conte, A, Corea, F, Cottone, S, Crociani, P, D'Andrea, F, Danni, M, De Luca, G, de Pascalis, D, De Riz, M, De Robertis, F, De Rosa, G, De Stefano, N, Della Corte, M, Di Sapio, A, Docimo, R, Falcini, M, Falcone, N, Fermi, S, Ferraro, E, Ferro, M, Fortunato, M, Foschi, M, Gajofatto, A, Gallo, A, Gallo, P, Gatto, M, Gazzola, P, Giordano, A, Granella, F, Grasso, M, Grimaldi, L, Iaffaldano, P, Immovilli, P, Imperiale, D, Inglese, M, Iodice, R, Leva, S, Leuzzi, V, Lugaresi, A, Lus, G, Maimone, D, Mancinelli, L, Maniscalco, G, Marfia, G, Margari, L, Marinelli, F, Marini, B, Marson, A, Mascoli, N, Massacesi, L, Melani, F, Merello, M, Fioretti, C, Mirabella, M, Montepietra, S, Nasuelli, D, Nicolao, P, Pasquali, L, Passantino, F, Pecori, C, Peresson, M, Pesci, I, Piantadosi, C, Piras, M, Pizzorno, M, Plewnia, K, Pozzilli, C, Protti, A, Quatrale, R, Realmuto, S, Ribizzi, G, Rinalduzzi, S, Rini, A, Romano, S, Filippi, M, Ronzoni, M, Rossi, P, Rovaris, M, Salemi, G, Santangelo, G, Santangelo, M, Leone, A, Sarchielli, P, Sinisi, L, Ferraro, D, Solaro, C, Spitaleri, D, Strumia, S, Tassinari, T, Santuccio, G, Tortorella, C, Totaro, R, Tozzo, A, Trivelli, G, Turano, G, Valentino, P, Venturi, S, Vianello, M, Zaffaroni, M, Zarbo, R, Mosconi P., Guerra T., Paletta P., D'Ettorre A., Ponzio M., Battaglia M. A., Amato M. P., Bergamaschi R., Capobianco M., Comi G., Gasperini C., Patti F., Pugliatti M., Ulivelli M., Trojano M., Lepore V., Aguglia U., Amato M., Ancona A., Ardito B., Avolio C., Balgera R., Banfi P., Barcella V., Barone P., Bellantonio P., Berardinelli A., Bertora P., Bianchi M., Bramanti P., Brescia Morra V., Brichetto G., Brioschi A., Buccafusca M., Bucello S., Busillo V., Calchetti B., Cantello R., Capone F., Capone L., Cargnelutti D., Carozzi M., Cartechini E., Cavaletti G., Cavalla P., Celani M., Clerici R., Clerico M., Cocco E., Torri Clerici V., Coniglio M., Conte A., Corea F., Cottone S., Crociani P., D'Andrea F., Danni M., De Luca G., de Pascalis D., De Riz M., De Robertis F., De Rosa G., De Stefano N., Della Corte M., Di Sapio A., Docimo R., Falcini M., Falcone N., Fermi S., Ferraro E., Ferro M., Fortunato M., Foschi M., Gajofatto A., Gallo A., Gallo P., Gatto M., Gazzola P., Giordano A., Granella F., Grasso M., Grimaldi L., Iaffaldano P., Immovilli P., Imperiale D., Inglese M., Iodice R., Leva S., Leuzzi V., Lugaresi A., Lus G., Maimone D., Mancinelli L., Maniscalco G., Marfia G., Margari L., Marinelli F., Marini B., Marson A., Mascoli N., Massacesi L., Melani F., Merello M., Fioretti C., Mirabella M., Montepietra S., Nasuelli D., Nicolao P., Pasquali L., Passantino F., Pecori C., Peresson M., Pesci I., Piantadosi C., Piras M., Pizzorno M., Plewnia K., Pozzilli C., Protti A., Quatrale R., Realmuto S., Ribizzi G., Rinalduzzi S., Rini A., Romano S., Filippi M., Ronzoni M., Rossi P., Rovaris M., Salemi G., Santangelo G., Santangelo M., Leone A., Sarchielli P., Sinisi L., Ferraro D., Solaro C., Spitaleri D., Strumia S., Tassinari T., Santuccio G., Tortorella C., Totaro R., Tozzo A., Trivelli G., Turano G., Valentino P., Venturi S., Vianello M., Zaffaroni M., and Zarbo R.
Abstract: Introduction: Over the years, disease registers have been increasingly considered a source of reliable and valuable population studies. However, the validity and reliability of data from registers may be limited by missing data, selection bias or data quality not adequately evaluated or checked. This study reports the analysis of the consistency and completeness of the data in the Italian Multiple Sclerosis and Related Disorders Register. Methods: The Register collects, through a standardized Web-based Application, unique patients. Data are exported bimonthly and evaluated to assess the updating and completeness, and to check the quality and consistency. Eight clinical indicators are evaluated. Results: The Register counts 77,628 patients registered by 126 centres. The number of centres has increased over time, as their capacity to collect patients. The percentages of updated patients (with at least one visit in the last 24 months) have increased from 33% (enrolment period 2000–2015) to 60% (enrolment period 2016–2022). In the cohort of patients registered after 2016, there were ≥ 75% updated patients in 30% of the small centres (33), in 9% of the medium centres (11), and in all the large centres (2). Clinical indicators show significant improvement for the active patients, expanded disability status scale every 6 months or once every 12 months, visits every 6 months, first visit within 1 year and MRI every 12 months. Conclusions: Data from disease registers provide guidance for evidence-based health policies and research, so methods and strategies ensuring their quality and reliability are crucial and have several potential applications.
Published: 2023

29. Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy

Author: Cavaletti, G, Pizzamiglio, C, Man, A, Engber, T, Comi, C, Wilbraham, D, Cavaletti G., Pizzamiglio C., Man A., Engber T. M., Comi C., Wilbraham D., Cavaletti, G, Pizzamiglio, C, Man, A, Engber, T, Comi, C, Wilbraham, D, Cavaletti G., Pizzamiglio C., Man A., Engber T. M., Comi C., and Wilbraham D.
Abstract: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and disabling dose-limiting toxicities of chemotherapy. We report here the results of two separate non-interventional studies (49 patients), which evaluated blood neurofilament light chain (NfL) as a biomarker of CIPN in breast cancer patients treated with paclitaxel. All patients underwent a standard treatment protocol that was established independently of the present studies. NfL was measured in serum using an ultrasensitive single-molecule array and compared with the self-administered European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale (CIPN20) and Total Neuropathy Score clinical version (TNSc), a clinician-reported measure of neuropathy progression. The TNSc increased with cumulative dose compared with baseline, and the NfL concentrations were also strongly associated with the cumulative dose of chemotherapy. The analysis showed a correlation between TNSc and NfL. Both TNSc and NfL showed weak to moderate associations with CIPN20 subscores, with a better association for the CIPN20 sensory compared with motor and autonomic subscores. Data from the two studies provide evidence that serum NfL has the potential to be used as a biomarker to monitor and mitigate CIPN. However, studies with additional patients planned in the ongoing clinical trial will determine the universal application of NfL as a biomarker in CIPN.
Published: 2023

30. Satellite Glial Cells in Chemotherapy Induced Peripheral Neuropathy

Author: Pozzi, E, Rodriguez-Menendez, V, Ballarini, E, Argentini, A, Canta, A, Chiorazzi, A, Alberti, P, Meregalli, C, Cavaletti, G, Carozzi, V, Pozzi E., Rodriguez-Menendez V., Ballarini E., Argentini A., Canta A., Chiorazzi A., Alberti P., Meregalli C., Cavaletti G., Carozzi VA., Pozzi, E, Rodriguez-Menendez, V, Ballarini, E, Argentini, A, Canta, A, Chiorazzi, A, Alberti, P, Meregalli, C, Cavaletti, G, Carozzi, V, Pozzi E., Rodriguez-Menendez V., Ballarini E., Argentini A., Canta A., Chiorazzi A., Alberti P., Meregalli C., Cavaletti G., and Carozzi VA.
Published: 2023

31. Editorial: Tubulin and axonal transport disturbances in CNS and PNS diseases

Author: Bartolini, F, Cavaletti, G, Bartolini F., Cavaletti G., Bartolini, F, Cavaletti, G, Bartolini F., and Cavaletti G.
Published: 2023

32. Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent

Author: Malacrida, A, Deschamps-Wright, M, Rigolio, R, Cavaletti, G, Miloso, M, Malacrida A., Deschamps-Wright M., Rigolio R., Cavaletti G., Miloso M., Malacrida, A, Deschamps-Wright, M, Rigolio, R, Cavaletti, G, Miloso, M, Malacrida A., Deschamps-Wright M., Rigolio R., Cavaletti G., and Miloso M.
Abstract: Rigosertib is a small molecule in preclinical development that, due to its characteristics as a dual PLK1 and PI3K inhibitor, is particularly effective in counteracting the advance of different types of tumors. In this work, we evaluated the efficacy of Rigosertib and the expression of p53 in five different human tumor cell lines in vitro, A549 (lung adenocarcinoma), MCF-7 and MDA-MB231 (breast cancer cells), RPMI 8226 (multiple myeloma), and U87-MG (glioblastoma). We demonstrated that in all cell lines, the effect was dose- and time-dependent, but A549 cells were the most sensible to the treatment while higher concentrations were required for the most resistant cell line U87-MG. Moreover, the highest and lowest p53 levels have been observed, respectively, in A459 and U87-MG cells. The alterations in the cell cycle and in cell-cycle-related proteins were observed in A549 at lower concentrations than U87-MG. In conclusion, with this article we have demonstrated that Rigosertib has different efficacy depending on the cell line considered and that it could be a potential antineoplastic agent against lung cancer in humans.
Published: 2023

33. Multimodal Comparison of Diabetic Neuropathy in Aged Streptozotocin-Treated Sprague–Dawley and Zucker Diabetic Fatty Rats

Author: Canta, A, Carozzi, V, Chiorazzi, A, Meregalli, C, Oggioni, N, Rodriguez-Menendez, V, Sala, B, Melcangi, R, Giatti, S, Lombardi, R, Bianchi, R, Marmiroli, P, Cavaletti, G, Canta A., Carozzi V. A., Chiorazzi A., Meregalli C., Oggioni N., Rodriguez-Menendez V., Sala B., Melcangi R. C., Giatti S., Lombardi R., Bianchi R., Marmiroli P., Cavaletti G., Canta, A, Carozzi, V, Chiorazzi, A, Meregalli, C, Oggioni, N, Rodriguez-Menendez, V, Sala, B, Melcangi, R, Giatti, S, Lombardi, R, Bianchi, R, Marmiroli, P, Cavaletti, G, Canta A., Carozzi V. A., Chiorazzi A., Meregalli C., Oggioni N., Rodriguez-Menendez V., Sala B., Melcangi R. C., Giatti S., Lombardi R., Bianchi R., Marmiroli P., and Cavaletti G.
Abstract: The development and progression of diabetic polyneuropathy (DPN) are due to multiple mechanisms. The creation of reliable animal models of DPN has been challenging and this issue has not yet been solved. However, despite some recognized differences from humans, most of the current knowledge on the pathogenesis of DPN relies on results achieved using rodent animal models. The simplest experimental DPN model reproduces type 1 diabetes, induced by massive chemical destruction of pancreatic beta cells with streptozotocin (STZ). Spontaneous/transgenic models of diabetes are less frequently used, mostly because they are less predictable in clinical course, more expensive, and require a variable time to achieve homogeneous metabolic conditions. Among them, Zucker diabetic fatty (ZDF) rats represent a typical type 2 diabetes model. Both STZ-induced and ZDF rats have been extensively used, but only very few studies have compared the long-term similarities and differences existing between these two models. Moreover, inconsistencies have been reported regarding several aspects of short-term in vivo studies using these models. In this study, we compared the long-term course of DPN in STZ-treated Sprague–Dawley and ZDF rats with a multimodal set of readout measures.
Published: 2023

34. Engineered mesoporous silica-based nanoparticles as smart chemotherapy nanodevice for bortezomib administration

Author: De Santo, M, Giovinazzo, A, Fava, M, Mazzotta, E, De Napoli, I, Greco, M, Comande, A, Nigro, A, Argurio, P, Perrotta, I, Davoli, M, Tagarelli, A, Elliani, R, Granato, T, Nicolini, G, Chiorazzi, A, Semperboni, S, Ballarini, E, Crocamo, C, Cavaletti, G, Lombardo, D, Sisci, D, Morelli, C, Leggio, A, Pasqua, L, De Santo M., Giovinazzo A., Fava M., Mazzotta E., De Napoli I. E., Greco M., Comande A., Nigro A., Argurio P., Perrotta I., Davoli M., Tagarelli A., Elliani R., Granato T., Nicolini G., Chiorazzi A., Semperboni S., Ballarini E., Crocamo C., Cavaletti G., Lombardo D., Sisci D., Morelli C., Leggio A., Pasqua L., De Santo, M, Giovinazzo, A, Fava, M, Mazzotta, E, De Napoli, I, Greco, M, Comande, A, Nigro, A, Argurio, P, Perrotta, I, Davoli, M, Tagarelli, A, Elliani, R, Granato, T, Nicolini, G, Chiorazzi, A, Semperboni, S, Ballarini, E, Crocamo, C, Cavaletti, G, Lombardo, D, Sisci, D, Morelli, C, Leggio, A, Pasqua, L, De Santo M., Giovinazzo A., Fava M., Mazzotta E., De Napoli I. E., Greco M., Comande A., Nigro A., Argurio P., Perrotta I., Davoli M., Tagarelli A., Elliani R., Granato T., Nicolini G., Chiorazzi A., Semperboni S., Ballarini E., Crocamo C., Cavaletti G., Lombardo D., Sisci D., Morelli C., Leggio A., and Pasqua L.
Abstract: Adverse reactions, toxicity, and poor compliance from patients still represent major challenges for conventional chemotherapy treatments. Localized drug delivery would ideally improve therapeutic efficacy, minimizing the side effects. An MSU-type mesoporous silica-based nanodevice (FOL-MSN-BTZ), able to selectively deliver the antineoplastic drug bortezomib (BTZ) to folate receptor over-expressing multiple myeloma (FR+ MM) cells is described. The receptor-specific ligand, folic acid, grafted on the external surface of the nanosystem, allows tumor recognition and cell internalization, while BTZ, mainly linked to the pore internal surface through a covalent pH-sensitive bond, is released in an acidic tumor environment. A detailed investigation showed that only the fine balancing of different functionalities of the nanodevice around the external and internal surfaces of MSN particles shows the absence of toxicity towards healthy cells in vitro and negligible BTZ-release at physiological pH, which are suitable features for applicative purposes in the engineering of therapies. After complete characterization in vitro, an accurate suspendability assessment, which considered the sedimentation process that reduces the particle amount and, consequently, drug content in the suspensions, allowed the development of an injectable formulation of FOL-MSN-BTZ that showed higher antitumor efficacy and an overall tendency to lower toxicity in a MM mice model compared to the conventional bortezomib chemotherapy.
Published: 2023

35. Self-Reported Assessment of the Socio-Economic Impact of Anticancer Chemotherapy-Related Neurotoxicity

Author: Cavaletti, G, D'Acunti, A, Porcu, A, Masiello, G, Del Campo, L, Traclo, G, De Lorenzo, F, Bernasconi, D, Cavaletti G., D'Acunti A., Porcu A., Masiello G., Del Campo L., Traclo G., De Lorenzo F., Bernasconi D. P., Cavaletti, G, D'Acunti, A, Porcu, A, Masiello, G, Del Campo, L, Traclo, G, De Lorenzo, F, Bernasconi, D, Cavaletti G., D'Acunti A., Porcu A., Masiello G., Del Campo L., Traclo G., De Lorenzo F., and Bernasconi D. P.
Abstract: Chemotherapy-induced neurotoxicity is a well-known complication of several very effective systemic anticancer treatments, mainly presenting as cognitive impairment (“chemo-brain”) and peripheral neuropathy. The social and economic effects of long-lasting chemotherapy-induced neurotoxicity on patients’ lifestyles and their relationships are under-investigated, and their impact is, therefore, largely unknown. In this study, we used a web-based questionnaire to record the self-reported perception of chemotherapy-induced neurotoxicity on cancer patients’ health status, but also on several different aspects of their daily life. From the study results, it emerged that the impact of chemotherapy-induced neurotoxicity on personal, social, and working activities is very high. A similar effect was also observed when the psychological impact is assessed. Moreover, there is evidence suggesting that the management of CIPN is suboptimal; this is partially due to a lack of effective drugs, but also of appropriate advice from healthcare providers. In conclusion, this study provides evidence for the relevance of the impact on the explored aspects of the daily life of cancer patients and spotlights the need for a larger and more structured investigation on these long-term side effects of anticancer chemotherapy.
Published: 2023

36. EXPLOITING HDAC6 SPECIFIC INHIBITORS TO REDUCE OHP-INDUCED NEUROTOXICITY

Author: Squarzoni, A, Donzelli, E, Alberti, P, Ballarini, E, Rodriguez Menendez, V, Scuteri, A, Cavaletti, G, Squarzoni A, Donzelli E, Alberti P, Ballarini E, Rodriguez Menendez V, Scuteri A, Cavaletti G, Squarzoni, A, Donzelli, E, Alberti, P, Ballarini, E, Rodriguez Menendez, V, Scuteri, A, Cavaletti, G, Squarzoni A, Donzelli E, Alberti P, Ballarini E, Rodriguez Menendez V, Scuteri A, and Cavaletti G
Published: 2023

37. HDAC inhibitors as antineoplastic and neuroprotective drugs: in vitro assessment

Author: Squarzoni, A, Alberti, P, Donzelli, E, Scuteri, A, Cavaletti, G, Squarzoni A, Alberti P, Donzelli E, Scuteri A, Cavaletti G, Squarzoni, A, Alberti, P, Donzelli, E, Scuteri, A, Cavaletti, G, Squarzoni A, Alberti P, Donzelli E, Scuteri A, and Cavaletti G
Published: 2023

38. ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier

Author: Dal Magro, R., Ornaghi, F., Cambianica, I., Beretta, S., Re, F., Musicanti, C., Rigolio, R., Donzelli, E., Canta, A., Ballarini, E., Cavaletti, G., Gasco, P., and Sancini, G.
Published: 2017
Full Text: View/download PDF

39. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)

Author: Kieffer, Jacobien M., Postma, Tjeerd J., van de Poll-Franse, Lonneke, Mols, Floortje, Heimans, Jan J., Cavaletti, Guido, Aaronson, Neil K., Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Valsecchi, M. G., Galimberti, S., Rossi, E., Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Piatti, M. L., Alberti, P., Binda, D., Bidoli, P., Cazzaniga, M., Cortinovis, D., Bruna, J., Velasco, R., Argyriou, A. A., Kalofonos, H. P., Psimaras, D., Ricard, D., Pace, A., Galiè, E., Briani, C., Lucchetta, M., Campagnolo, M., Torre, C. Dalla, Faber, C. G., Merkies, I. S. J., Vanhoutte, E. K., Bakkers, M., Brouwer, B., Boogerd, M., Lalisang, R. I., Boogerd, W., Brandsma, D., Koeppen, S., Hense, J., Grant, R., Storey, D., Kerrigan, S., Schenone, A., Reni, L., Piras, B., Fabbri, S., Pessino, A., Padua, L., Granata, G., Leandri, M., Ghignotti, I., Plasmati, R., Pastorelli, F., Postma, T. J., Heimans, J. J., Eurelings, M., Meijer, R. J., Grisold, W., Pozza, E. Lindeck, Mazzeo, A., Toscano, A., Russo, M., Tomasello, C., Altavilla, G., Prado, M. Penas, Gonzalez, C. Dominguez, Dorsey, S. G., and In Collaboration with the CI-PeriNomS Group
Published: 2017
Full Text: View/download PDF

40. Histone deacetylases inhibitors: a new frontier for neuroprotection?

Author: Squarzoni, A, Donzelli, E, Alberti, P, Ballarini, E, Rodriguez Menendez, V, Scuteri, A, Cavaletti, G, Squarzoni, A, Donzelli, E, Alberti, P, Ballarini, E, Rodriguez Menendez, V, Scuteri, A, and Cavaletti, G
Subjects: HDAC, HDACi, neurotoxicity
Published: 2023

41. Peripheral Neurotoxic Medications in CMT Patients

Author: Cavaletti, G, Forsey, K, Alberti P, Cavaletti, G, Forsey, K, and Alberti, P
Subjects: CMT, neurotoxic drugs, neuropathy, Charcot-Marie-Tooth
Published: 2023

42. Acute and chronic Oxaliplatin-induced peripheral neurotoxicity: two sides of the same coin

Author: Alberti, P, Canta, A, Chiorazzi, A, Pozzi, E, Ballarini, E, Rodriguez-Menendez, V, Marmiroli, P, Cavaletti, G, Alberti, P, Canta, A, Chiorazzi, A, Pozzi, E, Ballarini, E, Rodriguez-Menendez, V, Marmiroli, P, and Cavaletti, G
Subjects: Nerve excitability testing, oxaliplatin neuropathy, histopathology, nerve morphometry, oxaliplatin neurotoxicity, animal models, translational medicine
Published: 2023

43. Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP

Author: Spina, E, Doneddu, P, Liberatore, G, Cocito, D, Fazio, R, Briani, C, Filosto, M, Benedetti, L, Antonini, G, Cosentino, G, Jann, S, Mazzeo, A, Cortese, A, Marfia, G, Clerici, A, Siciliano, G, Carpo, M, Luigetti, M, Lauria, G, Rosso, T, Cavaletti, G, Peci, E, Tronci, S, Ruiz, M, Piccinelli, S, Schenone, A, Leonardi, L, Gentile, L, Piccolo, L, Mataluni, G, Santoro, L, Nobile-Orazio, E, Manganelli, F, Spina E., Doneddu P. E., Liberatore G., Cocito D., Fazio R., Briani C., Filosto M., Benedetti L., Antonini G., Cosentino G., Jann S., Mazzeo A., Cortese A., Marfia G. A., Clerici A. M., Siciliano G., Carpo M., Luigetti M., Lauria G., Rosso T., Cavaletti G., Peci E., Tronci S., Ruiz M., Piccinelli S. C., Schenone A., Leonardi L., Gentile L., Piccolo L., Mataluni G., Santoro L., Nobile-Orazio E., Manganelli F., Spina, E, Doneddu, P, Liberatore, G, Cocito, D, Fazio, R, Briani, C, Filosto, M, Benedetti, L, Antonini, G, Cosentino, G, Jann, S, Mazzeo, A, Cortese, A, Marfia, G, Clerici, A, Siciliano, G, Carpo, M, Luigetti, M, Lauria, G, Rosso, T, Cavaletti, G, Peci, E, Tronci, S, Ruiz, M, Piccinelli, S, Schenone, A, Leonardi, L, Gentile, L, Piccolo, L, Mataluni, G, Santoro, L, Nobile-Orazio, E, Manganelli, F, Spina E., Doneddu P. E., Liberatore G., Cocito D., Fazio R., Briani C., Filosto M., Benedetti L., Antonini G., Cosentino G., Jann S., Mazzeo A., Cortese A., Marfia G. A., Clerici A. M., Siciliano G., Carpo M., Luigetti M., Lauria G., Rosso T., Cavaletti G., Peci E., Tronci S., Ruiz M., Piccinelli S. C., Schenone A., Leonardi L., Gentile L., Piccolo L., Mataluni G., Santoro L., Nobile-Orazio E., and Manganelli F.
Abstract: Compression of the median nerve at the carpal tunnel can give demyelinating features and result in distal motor latency (DML) prolongation fulfilling the EFNS/PNS demyelinating criteria for chronic inflammatory demyelinating polyneuropathy (CIDP). Accordingly, being carpal tunnel syndrome (CTS) common in the general population, the EFNS/PNS guidelines recommend excluding the DML of the median nerve when DML prolongation may be consistent with median neuropathy at the wrist from CTS. The main aims of this study were to verify whether the inclusion of DML of the median nerve (when consistent with CTS) could improve electrophysiological diagnostic accuracy for CIDP and if the median nerve at the carpal tunnel was more prone to demyelination. We analyzed electrophysiological data from 499 patients included consecutively into the Italian CIDP Database. According to the EFNS/PNS criteria, 352 patients had a definite, 10 a probable, and 57 a possible diagnosis of CIDP, while 80 were not fulfilling the diagnostic criteria. The inclusion of DML prolongation of median nerve did not improve significantly the diagnostic accuracy for CIDP; overall diagnostic class changed in 6 out of 499 patients (1.2%) and electrodiagnostic class of CIDP changed from not fulfilling to possible in only 2 patients (2.5% of not-fulfilling patients). In conclusion, we can infer that excluding DML prolongation of median nerve does not increase the risk of missing a diagnosis of CIDP thus corroborating the current EFNS/PNS criteria.
Published: 2022

44. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values

Author: Arends, S, Drenthen, J, van den Bergh, P, Franssen, H, Hadden, R, Islam, B, Kuwabara, S, Reisin, R, Shahrizaila, N, Amino, H, Antonini, G, Attarian, S, Balducci, C, Barroso, F, Bertorini, T, Binda, D, Brannagan, T, Buermann, J, Casasnovas, C, Cavaletti, G, Chao, C, Dimachkie, M, Fulgenzi, E, Galassi, G, Gutierrez Gutierrez, G, Harbo, T, Hartung, H, Hsieh, S, Kiers, L, Lehmann, H, Manganelli, F, Marfia, G, Mataluni, G, Pardo, J, Pereon, Y, Rajabally, Y, Santoro, L, Sekiguchi, Y, Stein, B, Stettner, M, Uncini, A, Verboon, C, Verhamme, C, Vytopil, M, Waheed, W, Wang, M, Zivkovic, S, Jacobs, B, Cornblath, D, Arends S., Drenthen J., van den Bergh P., Franssen H., Hadden R. D. M., Islam B., Kuwabara S., Reisin R. C., Shahrizaila N., Amino H., Antonini G., Attarian S., Balducci C., Barroso F., Bertorini T., Binda D., Brannagan T. H., Buermann J., Casasnovas C., Cavaletti G., Chao C. -C., Dimachkie M. M., Fulgenzi E. A., Galassi G., Gutierrez Gutierrez G., Harbo T., Hartung H. -P., Hsieh S. -T., Kiers L., Lehmann H. C., Manganelli F., Marfia G. A., Mataluni G., Pardo J., Pereon Y., Rajabally Y. A., Santoro L., Sekiguchi Y., Stein B., Stettner M., Uncini A., Verboon C., Verhamme C., Vytopil M., Waheed W., Wang M., Zivkovic S., Jacobs B. C., Cornblath D. R., Arends, S, Drenthen, J, van den Bergh, P, Franssen, H, Hadden, R, Islam, B, Kuwabara, S, Reisin, R, Shahrizaila, N, Amino, H, Antonini, G, Attarian, S, Balducci, C, Barroso, F, Bertorini, T, Binda, D, Brannagan, T, Buermann, J, Casasnovas, C, Cavaletti, G, Chao, C, Dimachkie, M, Fulgenzi, E, Galassi, G, Gutierrez Gutierrez, G, Harbo, T, Hartung, H, Hsieh, S, Kiers, L, Lehmann, H, Manganelli, F, Marfia, G, Mataluni, G, Pardo, J, Pereon, Y, Rajabally, Y, Santoro, L, Sekiguchi, Y, Stein, B, Stettner, M, Uncini, A, Verboon, C, Verhamme, C, Vytopil, M, Waheed, W, Wang, M, Zivkovic, S, Jacobs, B, Cornblath, D, Arends S., Drenthen J., van den Bergh P., Franssen H., Hadden R. D. M., Islam B., Kuwabara S., Reisin R. C., Shahrizaila N., Amino H., Antonini G., Attarian S., Balducci C., Barroso F., Bertorini T., Binda D., Brannagan T. H., Buermann J., Casasnovas C., Cavaletti G., Chao C. -C., Dimachkie M. M., Fulgenzi E. A., Galassi G., Gutierrez Gutierrez G., Harbo T., Hartung H. -P., Hsieh S. -T., Kiers L., Lehmann H. C., Manganelli F., Marfia G. A., Mataluni G., Pardo J., Pereon Y., Rajabally Y. A., Santoro L., Sekiguchi Y., Stein B., Stettner M., Uncini A., Verboon C., Verhamme C., Vytopil M., Waheed W., Wang M., Zivkovic S., Jacobs B. C., and Cornblath D. R.
Abstract: Objective: To describe the heterogeneity of electrodiagnostic (EDx) studies in Guillain-Barré syndrome (GBS) patients collected as part of the International GBS Outcome Study (IGOS). Methods: Prospectively collected clinical and EDx data were available in 957 IGOS patients from 115 centers. Only the first EDx study was included in the current analysis. Results: Median timing of the EDx study was 7 days (interquartile range 4–11) from symptom onset. Methodology varied between centers, countries and regions. Reference values from the responding 103 centers were derived locally in 49%, from publications in 37% and from a combination of these in the remaining 15%. Amplitude measurement in the EDx studies (baseline-to-peak or peak-to-peak) differed from the way this was done in the reference values, in 22% of motor and 39% of sensory conduction. There was marked variability in both motor and sensory reference values, although only a few outliers accounted for this. Conclusions: Our study showed extensive variation in the clinical practice of EDx in GBS patients among IGOS centers across the regions. Significance: Besides EDx variation in GBS patients participating in IGOS, this diversity is likely to be present in other neuromuscular disorders and centers. This underlines the need for standardization of EDx in future multinational GBS studies.
Published: 2022

45. Clinical and preclinical features of eribulin-related peripheral neuropathy

Author: Tarasiuk, O, Cavaletti, G, Meregalli, C, Tarasiuk O., Cavaletti G., Meregalli C., Tarasiuk, O, Cavaletti, G, Meregalli, C, Tarasiuk O., Cavaletti G., and Meregalli C.
Abstract: Different microtubule-targeting agents (MTAs) possess distinct modes of action and their clinical use in cancer treatment is often limited by chemotherapy-induced peripheral neurotoxicity (CIPN). Eribulin is a member of the halichondrin class of antineoplastic drugs, which is correlated with a high antimitotic activity against metastatic breast cancer and liposarcoma. Current clinical evidence suggests that eribulin treatment, unlike some of the other MTAs, is associated with a relatively low incidence of severe peripheral neuropathy. This suggests that different MTAs possess unique mechanisms of neuropathologic induction. Animal models reliably reproduced eribulin-related neuropathy providing newer insights in CIPN pathogenesis, and they are highly suitable for in vivo functional, symptomatic and morphological characterizations of eribulin-related CIPN. The purpose of this review is to discuss the most recent literature on eribulin with a focus on both clinical and preclinical data, to explain the molecular events responsible for its favorable neurotoxic profile.
Published: 2022

46. The neurophysiological lesson from the Italian CIDP database

Author: Spina, E, Doneddu, P, Liberatore, G, Cocito, D, Fazio, R, Briani, C, Filosto, M, Benedetti, L, Antonini, G, Cosentino, G, Jann, S, Mazzeo, A, Cortese, A, Marfia, G, Clerici, A, Siciliano, G, Carpo, M, Luigetti, M, Lauria, G, Rosso, T, Cavaletti, G, Peci, E, Tronci, S, Ruiz, M, Piccinelli, S, Schenone, A, Leonardi, L, Gentile, L, Piccolo, L, Mataluni, G, Santoro, L, Nobile-Orazio, E, Manganelli, F, Spina E., Doneddu P. E., Liberatore G., Cocito D., Fazio R., Briani C., Filosto M., Benedetti L., Antonini G., Cosentino G., Jann S., Mazzeo A., Cortese A., Marfia G. A., Clerici A. M., Siciliano G., Carpo M., Luigetti M., Lauria G., Rosso T., Cavaletti G., Peci E., Tronci S., Ruiz M., Piccinelli S. C., Schenone A., Leonardi L., Gentile L., Piccolo L., Mataluni G., Santoro L., Nobile-Orazio E., Manganelli F., Spina, E, Doneddu, P, Liberatore, G, Cocito, D, Fazio, R, Briani, C, Filosto, M, Benedetti, L, Antonini, G, Cosentino, G, Jann, S, Mazzeo, A, Cortese, A, Marfia, G, Clerici, A, Siciliano, G, Carpo, M, Luigetti, M, Lauria, G, Rosso, T, Cavaletti, G, Peci, E, Tronci, S, Ruiz, M, Piccinelli, S, Schenone, A, Leonardi, L, Gentile, L, Piccolo, L, Mataluni, G, Santoro, L, Nobile-Orazio, E, Manganelli, F, Spina E., Doneddu P. E., Liberatore G., Cocito D., Fazio R., Briani C., Filosto M., Benedetti L., Antonini G., Cosentino G., Jann S., Mazzeo A., Cortese A., Marfia G. A., Clerici A. M., Siciliano G., Carpo M., Luigetti M., Lauria G., Rosso T., Cavaletti G., Peci E., Tronci S., Ruiz M., Piccinelli S. C., Schenone A., Leonardi L., Gentile L., Piccolo L., Mataluni G., Santoro L., Nobile-Orazio E., and Manganelli F.
Abstract: Introduction: Electrophysiological diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) may be challenging. Thus, with the aim ofproviding some practical advice in electrophysiological approach to a patient with suspected CIDP, we analyzed electrophysiological data from 499 patients enrolled inthe Italian CIDP Database. Methods: We calculated the rate of each demyelinating feature, the rate of demyelinating features per nerve, the diagnostic rate for upper andlower limb nerves, and, using a ROC curve analysis, the diagnostic accuracy of each couple of nerves and each demyelinating feature, for every CIDP subtype.Moreover, we compared the electrophysiological data of definite and probable CIDP patients with those of possible and not-fulfilling CIDP patients, and by a logisticregression analysis, we estimated the odds ratio (OR) to make an electrophysiological diagnosis of definite or probable CIDP. Results: The ulnar nerve had the highestrate of demyelinating features and, when tested bilaterally, had the highest diagnostic accuracy except for DADS in which peroneal nerves were the most informative.In possible and not-fulfilling CIDP patients, a lower number of nerves and proximal temporal dispersion (TD) measurements had been performed compared to definiteand probable CIDP patients. Importantly, OR for each tested motor nerve and each TD measurement was 1.59 and 1.33, respectively. Conclusion: Our findingsdemonstrated that the diagnosis of CIDP may be missed due to inadequate or incomplete electrophysiological examination or interpretation. At the same time, thesedata taken together could be useful to draw a thoughtful electrophysiological approach to patients suspected of CIDP.
Published: 2022

47. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients with Primary Progressive Multiple Sclerosis

Author: Portaccio, E, Fonderico, M, Iaffaldano, P, Pasto, L, Razzolini, L, Bellinvia, A, De Luca, G, Ragonese, P, Patti, F, Brescia Morra, V, Cocco, E, Sola, P, Inglese, M, Lus, G, Pozzilli, C, Maimone, D, Lugaresi, A, Gazzola, P, Comi, G, Pesci, I, Spitaleri, D, Rezzonico, M, Vianello, M, Avolio, C, Logullo, F, Granella, F, Salvetti, M, Zaffaroni, M, Lucisano, G, Filippi, M, Trojano, M, Amato, M, Cavaletti, G, Portaccio E., Fonderico M., Iaffaldano P., Pasto L., Razzolini L., Bellinvia A., De Luca G., Ragonese P., Patti F., Brescia Morra V., Cocco E., Sola P., Inglese M., Lus G., Pozzilli C., Maimone D., Lugaresi A., Gazzola P., Comi G., Pesci I., Spitaleri D., Rezzonico M., Vianello M., Avolio C., Logullo F. O., Granella F., Salvetti M., Zaffaroni M., Lucisano G., Filippi M., Trojano M., Amato M. P., Cavaletti G., Portaccio, E, Fonderico, M, Iaffaldano, P, Pasto, L, Razzolini, L, Bellinvia, A, De Luca, G, Ragonese, P, Patti, F, Brescia Morra, V, Cocco, E, Sola, P, Inglese, M, Lus, G, Pozzilli, C, Maimone, D, Lugaresi, A, Gazzola, P, Comi, G, Pesci, I, Spitaleri, D, Rezzonico, M, Vianello, M, Avolio, C, Logullo, F, Granella, F, Salvetti, M, Zaffaroni, M, Lucisano, G, Filippi, M, Trojano, M, Amato, M, Cavaletti, G, Portaccio E., Fonderico M., Iaffaldano P., Pasto L., Razzolini L., Bellinvia A., De Luca G., Ragonese P., Patti F., Brescia Morra V., Cocco E., Sola P., Inglese M., Lus G., Pozzilli C., Maimone D., Lugaresi A., Gazzola P., Comi G., Pesci I., Spitaleri D., Rezzonico M., Vianello M., Avolio C., Logullo F. O., Granella F., Salvetti M., Zaffaroni M., Lucisano G., Filippi M., Trojano M., Amato M. P., and Cavaletti G.
Abstract: Importance: Except for ocrelizumab, treatment options in primary progressive multiple sclerosis (PPMS) are lacking. Objective: To investigate the effectiveness of DMTs on the risk of becoming wheelchair dependent in a real-world population of patients with PPMS. Design, Setting, and Participants: This was a multicenter, observational, retrospective, comparative effectiveness research study. Data were extracted on November 28, 2018, from the Italian multiple sclerosis register and analyzed from June to December 2021. Mean study follow-up was 11 years. Included in the study cohort were patients with a diagnosis of PPMS and at least 3 years of Expanded Disability Status Scale (EDSS) evaluations and 3 years of follow-up. Main Outcomes and Measures: The risk of reaching an EDSS score of 7.0 was assessed through multivariable Cox regression models. Exposures: Patients who received DMT before the outcome were considered treated. DMT was assessed as a time-dependent variable and by class of DMT (moderately and highly effective). Results: From a total of 3298 patients with PPMS, 2633 were excluded because they did not meet the entry criteria for the phase 3, multicenter, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with PPMS (ORATORIO) trial. Among the remaining 665 patients (mean [SD] age, 43.0 [10.7] years; 366 female patients [55.0%]), 409 were further selected for propensity score matching (288 treated and 121 untreated patients). In the matched cohort, during the study follow-up, 37% of patients (152 of 409) reached an EDSS score of 7.0 after a mean (SD) follow-up of 10.6 (5.6) years. A higher EDSS score at baseline (adjusted hazard ratio [aHR], 1.32; 95% CI, 1.13-1.55; P <.001), superimposed relapses (aHR, 2.37; 95% CI, 1.24-4.54; P =.009), and DMT exposure (aHR, 1.75; 95% CI, 1.04-2.94; P =.03) were associated with a higher risk of an EDSS score of 7.0, whereas the interaction term b
Published: 2022

48. Ubiquitin Proteasome System and Microtubules Are Master Regulators of Central and Peripheral Nervous System Axon Degeneration

Author: Cartelli, D, Cavaletti, G, Lauria, G, Meregalli, C, Cartelli D., Cavaletti G., Lauria G., Meregalli C., Cartelli, D, Cavaletti, G, Lauria, G, Meregalli, C, Cartelli D., Cavaletti G., Lauria G., and Meregalli C.
Abstract: Axonal degeneration is an active process that differs from neuronal death, and it is the hallmark of many disorders affecting the central and peripheral nervous system. Starting from the analyses of Wallerian degeneration, the simplest experimental model, here we describe how the long projecting neuronal populations affected in Parkinson’s disease and chemotherapy-induced peripheral neuropathies share commonalities in the mechanisms and molecular players driving the earliest phase of axon degeneration. Indeed, both dopaminergic and sensory neurons are particularly susceptible to alterations of microtubules and axonal transport as well as to dysfunctions of the ubiquitin proteasome system and protein quality control. Finally, we report an updated review on current knowledge of key molecules able to modulate these targets, blocking the on-going axonal degeneration and inducing neuronal regeneration. These molecules might represent good candidates for disease-modifying treatment, which might expand the window of intervention improving patients’ quality of life.
Published: 2022

49. Rigosertib and cholangiocarcinoma: A cell cycle affair

Author: Malacrida, A, Cavaletti, G, Miloso, M, Malacrida A., Cavaletti G., Miloso M., Malacrida, A, Cavaletti, G, Miloso, M, Malacrida A., Cavaletti G., and Miloso M.
Abstract: Rigosertib is multi-kinase inhibitor that could represent an interesting therapeutic option for non-resectable patients with cholangiocarcinoma, a very aggressive hepatic cancer with limited effective treatments. The Western blotting technique was used to evaluate alterations in the expression of proteins involved in the regulation of the cell cycle of cholangiocarcinoma EGI-1 cells. Our results show an increase in EMI1 and Cyclin B protein levels after Rigosertib treatment. Moreover, the phosphorylation of CDK1 is significantly reduced by Rigosertib, while PLK1 expression increased after 24 h of treatment and decreased after 48 h. Finally, we evaluated the role of p53. Its levels increase after Rig treatment, and, as shown in the cell viability experiment with the p53 inhibitor Pifithrin, its activity is necessary for the effects of Rigosertib against the cell viability of EGI-1 cells. In conclusion, we hypothesized the mechanism of the action of Rigosertib against cholangiocarcinoma EGI-1 cells, highlighting the importance of proteins involved in the regulation of cell cycles. The CDK1-Cyclin B complex and p53 play an important role, explaining the Block in the G2/M phase of the cell cycle and the effect on cell viability.
Published: 2022

50. Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database

Author: Liberatore, G, De Lorenzo, A, Giannotta, C, Manganelli, F, Filosto, M, Cosentino, G, Cocito, D, Briani, C, Cortese, A, Fazio, R, Lauria, G, Clerici, A, Rosso, T, Marfia, G, Antonini, G, Cavaletti, G, Carpo, M, Doneddu, P, Spina, E, Cotti Piccinelli, S, Peci, E, Querol, L, Nobile-Orazio, E, Liberatore G., De Lorenzo A., Giannotta C., Manganelli F., Filosto M., Cosentino G., Cocito D., Briani C., Cortese A., Fazio R., Lauria G., Clerici A. M., Rosso T., Marfia G. A., Antonini G., Cavaletti G., Carpo M., Doneddu P. E., Spina E., Cotti Piccinelli S., Peci E., Querol L., Nobile-Orazio E., Liberatore, G, De Lorenzo, A, Giannotta, C, Manganelli, F, Filosto, M, Cosentino, G, Cocito, D, Briani, C, Cortese, A, Fazio, R, Lauria, G, Clerici, A, Rosso, T, Marfia, G, Antonini, G, Cavaletti, G, Carpo, M, Doneddu, P, Spina, E, Cotti Piccinelli, S, Peci, E, Querol, L, Nobile-Orazio, E, Liberatore G., De Lorenzo A., Giannotta C., Manganelli F., Filosto M., Cosentino G., Cocito D., Briani C., Cortese A., Fazio R., Lauria G., Clerici A. M., Rosso T., Marfia G. A., Antonini G., Cavaletti G., Carpo M., Doneddu P. E., Spina E., Cotti Piccinelli S., Peci E., Querol L., and Nobile-Orazio E.
Abstract: Objective: To investigate the frequency and clinical correlates of anti-nerve autoantibodies in an unselected series of Italian patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) Methods: Sera from 276 CIDP patients fulfilling the EFNS/PNS criteria and included in the Italian CIDP database were examined for the presence of anti-nerve autoantibodies. Results were correlated with the clinical data collected in the database. Results: Anti-neurofascin155 (NF155) antibodies were found in 9/258 (3.5%) patients, anti-contactin1 (CNTN1) antibodies in 4/258 (1.6%) patients, and anti-contactin-associated protein1 (Caspr1) in 1/197 (0.5%) patients, while none had reactivity to gliomedin or neurofascin 186. Predominance of IgG4 isotype was present in 7of the 9 examined patients. Anti-NF155 patients more frequently had ataxia, tremor, and higher CSF protein levels than antibody-negative patients. Anti-CNTN1 patients more frequently had a GBS-like onset, pain, and ataxia and had more severe motor impairment at enrollment than antibody-negative patients. They more frequently received plasmapheresis, possibly reflecting a less satisfactory response to IVIg or steroids. IgM antibodies against one or more gangliosides were found in 6.5% of the patients (17/260) and were more frequently directed against GM1 (3.9%). They were frequently associated with a progressive course, with a multifocal sensorimotor phenotype and less frequent cranial nerve involvement and ataxia. Conclusions: Anti-paranodal and anti-ganglioside antibodies are infrequent in patients with CIDP but are associated with some typical clinical association supporting the hypothesis that CIDP might be a pathogenically heterogeneous syndrome possibly explaining the different clinical presentations.
Published: 2022

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

2,156 results on '"Cavaletti, G."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources